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ttp://dx.doi.org/10.1016/j.jmoldx.2016.11.001Objectives: To develop evidence-based guideline recommendations through a systematic review of the
literature to establish standard molecular biomarker testing of colorectal cancer (CRC) tissues to guide
epidermal growth factor receptor (EGFR) therapies and conventional chemotherapy regimens.
Methods: The American Society for Clinical Pathology, College of American Pathologists, Association for
Molecular Pathology, and American Society of Clinical Oncology convened an expert panel to develop an
evidence-based guideline to establish standard molecular biomarker testing and guide therapies for
patients with CRC. A comprehensive literature search that included more than 4,000 articles was
conducted.
Results: Twenty-one guideline statements were established.
Conclusions: Evidence supports mutational testing for EGFR signaling pathway genes, since
they provide clinically actionable information as negative predictors of benefit to anti-EGFR
monoclonal antibody therapies for targeted therapy of CRC. Mutations in several of the bio-
markers have clear prognostic value. Laboratory approaches to operationalize CRC molecular testing
are presented.
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Sepulveda et alMolecular testing to select targeted and conventional ther- and sensitivity meet the clinical needs. While earlier testing
apies for patients with colorectal cancer (CRC) has been the
focus of a number of recent studies and is becoming stan-
dard practice for management of patients with CRC. Mo-
lecular markers that predict response to a specific therapy or
treatment regimen are known as predictive biomarkers.1
Monoclonal antibody therapies that target the epidermal
growth factor receptor (EGFR) bind the EGFR extracellular
domain, blocking EGFR signaling pathways. Anti-EGFR
monoclonal antibodies have been the main targeted thera-
pies for CRC that require knowledge of the mutational
status of genes in the pathway as predictive biomarkers of
response to these therapies.2-4 Initial clinical trial data
demonstrated that patients with CRC carrying activating
mutations of KRAS affecting exon 2 codons 12 and 13
did not benefit from anti-EGFR monoclonal antibody
therapy.2-4 Subsequent studies described other mutations in
genes of the EGFR signaling pathways involving other
exons of KRAS and in NRAS, BRAF, PIK3CA, and PTEN
that may affect response of CRC to anti-EGFR antibody
therapies. Guidelines addressing the molecular testing of
EGFR pathway genes beyond KRAS have not been estab-
lished and are needed in clinical practice.
The DNA mismatch repair (MMR) status of CRC may
have predictive value in some clinical settings. While testing
of CRC for MMR has been recommended for all patients
with CRC as a workup test to evaluate for possible Lynch
syndrome,5 guidelines for the use of MMR as a predictive
biomarker of response to therapy have not been reported.
Recent molecular biomarker data have shown the impor-
tance of microsatellite instability (MSI) testing, a marker of
deficient mismatch repair (dMMR), for the selection of
patients for immunotherapy (see section on emerging bio-
markers below).
Alterations of a number of critical genes in CRC devel-
opment and progression such as dMMR and BRAF acti-
vating mutations have been shown to affect prognosis, as
measured by several metrics of tumor progression or sur-
vival.6-8 The utility of incorporating prognostic biomarkers
in the management of patients with CRC has not been well
defined in clinical practice. Defining the utility of informa-
tion gathered from prognostic molecular biomarkers for
clinical management of patients with CRC is warranted.
The postgenome era and the emphasis on precision
genomic-based medicine are providing enormous amounts
of new data and many promising new molecular cancer
biomarkers that may emerge as molecular diagnostic tools
that can be used to enhance successful treatment of patients
with CRC and other cancers. Laboratories and regulatory
agencies are faced with challenges to rapidly and efficiently
provide new test results for the management of patients with
cancer. Laboratory testing of molecular biomarkers involves
the selection of assays, type of specimens to be tested,
timing of ordering of tests, and turnaround time for testing
results. Recent years have shown that a plethora of technical
approaches can effectively be used as long as test specificity188approaches were focused on one or a few testing targets, the
current need for multiple molecular markers from poten-
tially minute tumor samples is leading to greater use of gene
panels such as targeted next-generation sequencing (NGS)
cancer panels, which can assay from a few to hundreds of
genes and amplicons with known mutational hotspots in
cancer.
There is a need for current evidence-based recommen-
dations for the molecular testing of CRC tissues to guide
EGFR-targeted therapies and conventional chemotherapy
regimens. Therefore, the current recommendations were
developed through collaboration of four societies: American
Society for Clinical Pathology (ASCP), College of Amer-
ican Pathologists (CAP), Association for Molecular Pa-
thology (AMP), and American Society of Clinical Oncology
(ASCO). This guideline follows well-established methods
used in their development as well as for regular updates,
such that new advances in the molecular testing for clinical
management of CRC can be integrated in future updates of
the guideline in a timely manner.Panel Composition
The ASCP, the CAP Pathology and Laboratory Quality
Center (the Center), the AMP, and the ASCO convened an
expert panel consisting of practicing pathologists, oncolo-
gists, geneticists, and a biostatistician with expertise and
experience in molecular biomarker testing and targeted
therapies for CRC. The ASCP, CAP, AMP, and ASCO
jointly approved the appointment of the project, cochairs,
and expert panel members. In addition, a methodologist
experienced in systematic review and guideline develop-
ment consulted with the panel throughout the project.Conflict of Interest Policy
Prior to acceptance on the expert or advisory panel, potential
members completed a joint guideline conflict of interest
(COI) disclosure process, whose policy and form (in effect
July 2011) require disclosure of material financial interest
in, or potential for benefit of significant value from, the
guideline’s development or its recommendations 12 months
prior through the time of publication. The potential mem-
bers completed the COI disclosure form, listing any rela-
tionship that could be interpreted as constituting an actual,
potential, or apparent conflict. All project participants were
required to disclose conflicts prior to beginning and
continuously throughout the project’s timeline. Disclosed
conflicts of the expert panel members are listed in Appendix 1
and Appendix 2.
The ASCP, CAP, AMP, and ASCO provided funding for
the administration of the project; no industry funds were
used in the development of the guideline. All panel mem-
bers volunteered their time and were not compensated forjmd.amjpathol.org - The Journal of Molecular Diagnostics
ASCP/CAP/AMP/ASCO CRC Biomarker Guidelinetheir involvement, except for the contracted methodologist.
Please see the Supplemental Digital Content (SDC) at http://
dx.doi.org/10.1016/j.jmoldx.2016.11.001 for full details on
the COI policy.
Objective
The scope of the project was to develop an evidence-based
guideline to help establish standard molecular biomarker
testing, guide targeted therapies, and advance personalized
care for patients with CRC. The panel addressed the
following key questions:
1. What biomarkers are useful to select patients with CRC
for targeted and conventional therapies?
2. How should tissue specimens be processed for biomarker
testing for CRC management?
3. How should biomarker testing for CRC management be
performed?
4. How should molecular testing of CRC be implemented
and operationalized?
5. Are there emerging genes/biomarkers that should be
routinely tested in CRC?Materials and Methods
This evidence-based guideline was developed following
standards as endorsed by the Institute of Medicine.9 A
detailed description of the methods and systematic review
(including the quality assessment and complete analysis of
the evidence) can be found in the SDC.
Literature Search and Selection
A comprehensive search for literature was performed in
MEDLINE using the OvidSP (August 1, 2013) and PubMed
(September 17, 2013) interfaces. The initial MEDLINE
search encompassed the publication dates of January 1, 2008,
through August 1, 2013 (OvidSP), and January 1, 2008,
through September 17, 2013 (PubMed). A supplemental
literature search was performed using Scopus (September 25,
2013) to identify relevant articles published between January
1, 2008, and September 25, 2013, in journals not indexed in
MEDLINE. The literature search of the electronic databases
involved two separate searches in each database, the first
using Medical Subject Headings (MeSH) terms and key-
words for the concepts “colorectal cancer,” “biomarkers,”
“treatment,” and “treatment outcomes” and the second using
terms for the concepts “colorectal cancer,” “biomarkers,” and
“laboratory methods.” Limits were set for human studies
published in English, and a publication filter was applied to
exclude lower levels of evidence such as letters, commen-
taries, editorials, and case reports. The Ovid search was rerun
on February 12, 2015, to identify articles published since
August 1, 2013.The Journal of Molecular Diagnostics - jmd.amjpathol.orgIn addition to the searches of electronic databases, an
Internet search of international health organizations, the
National Guidelines Clearinghouse, and Guidelines Interna-
tional Network was conducted for existing relevant guide-
lines or protocols. Guidelines were included if they were
published since 2008 in English. The proceedings of the
meetings of the ASCO and ASCO-Gastrointestinal Cancers
Symposium, European Society for Medical Oncology, and
the American Association for Cancer Research from 2012
and 2013 were also searched for relevant abstracts.
A focused examination of all systematic reviews retrieved
by the initial literature search and retained after full-text
review was performed to identify primary research studies
not already included. In addition, recommendations from
the expert panel were reviewed, and the reference lists of all
articles deemed eligible for inclusion were scanned for
relevant reports. The results of all searches were combined
and deduplicated.
Detailed information regarding the literature search
strategy can be found in the SDC.
Eligible Study Designs
Practice guidelines, consensus documents, systematic re-
views, meta-analyses, randomized controlled trials, compar-
ative studies, reviews, and evaluation studies were eligible for
inclusion. In addition to journal articles, the search identified
meeting abstracts.
Inclusion Criteria
Published studies were selected for full-text review if they
met each of the following criteria:
1. Patients with colorectal or rectal cancer with a pathology
diagnosis of adenocarcinoma or adenocarcinoma with
neuroendocrine differentiation, either primary or metastatic
2. Patients of all ages
3. Patients with cancer of any invasive stage (T1-T4)
4. Biomarker testing such asKRAS (Kirsten rat sarcoma viral
oncogene homolog), DNA MMR/MSI, BRAF (V-raf mu-
rine sarcoma viral oncogene homolog B1), NRAS [neuro-
blastoma RAS viral (v-ras) oncogene homolog], PIK3CA
(phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic
subunit alpha), PTEN (phosphatase and tensin homolog),
MLH1 (MutL homolog 1) methylation, or gene expression
profiles
5. Comparative studies
6. Human studies
7. Studies published in English
Exclusion Criteria
1. All other tumor primaries and types (ie, noncolorectal or
nonrectal cancers, tumor types other than adenocarci-
noma or adenocarcinoma with neuroendocrine
differentiation)189
Sepulveda et al2. Patients with noninvasive tumors (ie, intraepithelial,
dysplasia, in situ, polyps without carcinoma)
3. Studies of colorectal cancers without biomarker testing,
novel biomarkersdfor example, VEG-F (vascular
endothelial growth factor), XRCC1 (X-ray repair com-
plementing defective repair in Chinese hamster cells 1),
IGF (insulin-like growth factor), ERCC (excision repair
cross-complementing rodent repair deficiency, comple-
mentation group 1), micro-RNA, TYMS (thymidylate
synthetase), GCC (guanylyl cyclase C), LINE (long
interspersed nucleotide element) methylation, CIMP
(CpG island methylator phenotype), HER2 (V-erb-b2
erythroblastic leukemia viral oncogene homolog 2), CIN
(chromosomal instability) status LOH (loss of heterozy-
gosity), and germline (genetics only) testing
4. Non-English-language articles
5. Animal studies
6. Studies published prior to 2002
7. Noncomparative studies, letters, commentaries, or
editorials
8. Studies that did not address at least one of the defined
inclusion criteria
9. Studies with fewer than 50 patients per comparison armOutcomes of Interest
The primary outcomes of interest included survival outcomes
and performance characteristics of laboratory testing assays.
Survival outcomes included overall survival (OS), disease-
free survival (DFS), progression-free survival (PFS),
recurrence-free survival, time to recurrence, response to
therapy (eg, complete and partial response). Laboratory data
and test performance characteristics included percent muta-
tion, concordance of testing methods, sensitivity of testing
methods, specificity of testing methods, concordance of
detected mutations between primary and metastatic muta-
tions [number (%) of cases with mutations vs number of cases
with no mutations in the gene of interest], and concordance of
mutations (synchronous primary vs metastatic, metachro-
nous primary vs metastatic, between synchronous metasta-
ses, between metachronous metastases).
Quality Assessment
An assessment of the quality of the evidence was performed
for all retained studies following application of the inclusionTable 1 Levels of Evidence*
Level Description
Level I Evidence derived from systematic reviews
Level II Evidence derived from randomized contro
Level III Evidence derived from comparative studie
Level IV Evidence without a comparator (eg, case
*Data derived from National Health and Medical Research Council.10
190and exclusion criteria by the methodologist. Using this
method, studies deemed to be of low quality would not be
excluded from the systematic review but would be retained
and their methodologic strengths and weaknesses discussed
where relevant. Studies would be assessed by confirming
the presence of items related to both internal and external
validity, which are all associated with methodologic rigor
and a decrease in the risk of bias. The quality assessment of
the studies was performed by determining the risk of bias by
assessing key indicators, based on study design, against
known criteria. (Refer to the SDC for detailed discussion of
the quality assessment.)
For strength of the evidence, the panel considered the level
of evidence, as well as its quantity and quality of included
studies. The level of evidence was based on the study design
as described in Table 1.10 In general, level I and II evidence is
considered most appropriate to answer clinical questions, but
in the absence of such high-quality evidence, the panel
considered data from lower quality studies. The quantity of
evidence refers to the number of studies and number of cases
included for each outcome in the recommendation. The
quality of studies reflects how well the studies were designed
to eliminate bias and threats to validity.
The appropriateness of the study design and data
collected, relevance and clarity of findings, and adequacy of
conclusions were evaluated. Each study was assessed indi-
vidually (refer to the SDC for individual assessments and
results) and then summarized by study type. Components
such as generalizability and applicability were also consid-
ered when determining the strength of evidence. A summary
of the overall quality of the evidence was given considering
the evidence in totality. Ultimately, the designation (ie,
rating or grade) of the strength of evidence is a judgment by
the expert panel of its level of confidence that the evidence
from the studies informing the recommendations reflects
true effect. Table 2 describes the grades for strength of
evidence.11Assessing the Strength of Recommendations
Development of recommendations requires that the panel
review the identified evidence and make a series of key
judgments (using procedures described in the SDC). Grades
for strength of recommendations were developed by the
CAP Pathology and Laboratory Quality Center and are
described in Table 3.11of appropriate level II studies and/or clinical practice guidelines
lled trials
s (eg, prospective cohort studies, retrospective cohort studies)
reports, case series, narrative reviews)
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Table 2 Grades for Strength of Evidence*
Designation Description Quality of Evidence
Convincing High confidence that available evidence reflects true effect.
Further research is very unlikely to change the confidence
in the estimate of effect.
High/intermediate quality of evidence
Adequate Moderate confidence that available evidence reflects true
effect. Further research is likely to have an important
impact on the confidence in estimate of effect and may
change the estimate.
Intermediate/low quality of evidence
Inadequate Little confidence that available evidence reflects true
effect. Further research is very likely to have an
important impact on the confidence in the estimate of
effect and is likely to change the estimate.
Low/insufficient quality of evidence and expert panel uses
formal consensus process to reach recommendation
Insufficient Evidence is insufficient to discern net effect. Any estimate
of effect is very uncertain.
Insufficient evidence and expert panel uses formal
consensus process to reach recommendation
*Adapted from Guyatt et al,11 by permission of BMJ Publishing Group Limited.
ASCP/CAP/AMP/ASCO CRC Biomarker GuidelineGuideline Revision
This guideline will be reviewed every 4 years or earlier in
the event of publication of substantive and high-quality
evidence that could potentially alter the original guideline
recommendations. If necessary, the entire panel will
reconvene to discuss potential changes. When appropriate,
the panel will recommend revision of the guideline to the
ASCP, CAP, AMP, and ASCO for review and approval.Disclaimer
Practice guidelines and consensus statements reflect the best
available evidence and expert consensus supported in
practice. They are intended to assist physicians and patients
in clinical decision making and to identify questions andTable 3 Grades for Strength of Recommendation*
Designation Recommendation
Strong recommendation Recommend for or against a particular mo
testing practice for colorectal cancer (ca
must or should )
Recommendation Recommend for or against a particular mo
testing practice for colorectal cancer (ca
should or may)
Expert consensus opinion Recommend for or against a particular mo
testing practice for colorectal cancer (ca
should or may)
No recommendation No recommendation for or against a partic
molecular testing practice for colorectal
*Data derived from Guyatt et al.11
The Journal of Molecular Diagnostics - jmd.amjpathol.orgsettings for further research. With the rapid flow of scientific
information, new evidence may emerge between the time a
practice guideline or consensus statement is developed and
when it is published or read. Guidelines and statements are
not continually updated and may not reflect the most recent
evidence. Guidelines and statements address only the topics
specifically identified therein and are not applicable to other
interventions, diseases, or stages of diseases. Furthermore,
guidelines and consensus statements cannot account for
individual variation among patients and cannot be consid-
ered inclusive of all proper methods of care or exclusive of
other treatments. It is the responsibility of the treating
physician or other health care provider, relying on inde-
pendent experience and knowledge, to determine the best
course of treatment for the patient. Accordingly, adherence
to any practice guideline or consensus statement is volun-
tary, with the ultimate determination regarding itsRationale
lecular
n include
Supported by convincing or adequate strength of
evidence, high or intermediate quality of
evidence, and clear benefit that outweighs any
harms
lecular
n include
Some limitations in strength of evidence (adequate
or inadequate) and quality of evidence
(intermediate or low), balance of benefits and
harms, values, or costs, but panel concludes that
there is sufficient evidence and/or benefit to
inform a recommendation
lecular
n include
Serious limitations in strength of evidence
(inadequate of insufficient), quality of evidence
(intermediate or low), balance of benefits and
harms, values, or costs, but panel consensus is
that a statement is necessary
ular
cancer
Insufficient evidence or agreement of the balance of
benefits and harms, values, or costs to provide a
recommendation
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Table 4 Guideline Statements and Strength of Recommendations
Guideline Statement Strength of Recommendation
1. Patients with colorectal carcinoma being considered for anti-EGFR therapy must receive RAS mutational
testing. Mutational analysis should include KRAS and NRAS codons 12 and 13 of exon 2, 59 and 61 of
exon 3, and 117 and 146 of exon 4 (“expanded” or “extended” RAS ).
Recommendation
2a. BRAF p.V600 [BRAF c.1799 (p.V600)] mutational analysis should be performed in colorectal cancer
tissue in patients with colorectal carcinoma for prognostic stratification.
Recommendation
2b. BRAF p.V600 mutational analysis should be performed in deficient MMR tumors with loss of MLH1 to
evaluate for Lynch syndrome risk. Presence of a BRAF mutation strongly favors a sporadic pathogenesis.
The absence of a BRAF mutation does not exclude risk of Lynch syndrome.
Recommendation
3. Clinicians should order mismatch repair status testing in patients with colorectal cancers for the
identification of patients at high risk for Lynch syndrome and/or prognostic stratification.
Recommendation
4. There is insufficient evidence to recommend BRAF c.1799 p.V600 mutational status as a predictive
molecular biomarker for response to anti-EGFR inhibitors.
No recommendation
5. There is insufficient evidence to recommend PIK3CA mutational analysis of colorectal carcinoma tissue
for therapy selection outside of a clinical trial.
Note: Retrospective studies have suggested improved survival with postoperative aspirin use in
patients whose colorectal carcinoma harbors a PIK3CA mutation.
No recommendation
6. There is insufficient evidence to recommend PTEN analysis (expression by immunohistochemistry or
deletion by fluorescence in situ hybridization) in colorectal carcinoma tissue for patients who are being
considered for therapy selection outside of a clinical trial.
No recommendation
7. Metastatic or recurrent colorectal carcinoma tissues are the preferred specimens for treatment predictive
biomarker testing and should be used if such specimens are available and adequate. In their absence,
primary tumor tissue is an acceptable alternative and should be used.
Expert consensus opinion
8. Formalin-fixed, paraffin-embedded tissue is an acceptable specimen for molecular biomarker mutational
testing in colorectal carcinoma. Use of other specimens (eg, cytology specimens) will require additional
adequate validation, as would any changes in tissue-processing protocols.
Expert consensus opinion
9. Laboratories must use validated colorectal carcinoma molecular biomarker testing methods with
sufficient performance characteristics for the intended clinical use. Colorectal carcinoma molecular
biomarker testing validation should follow accepted standards for clinical molecular diagnostics tests.
Strong recommendation
10. Performance of molecular biomarker testing for colorectal carcinoma must be validated in accordance
with best laboratory practices.
Strong recommendation
11. Laboratories must validate the performance of IHC testing for colorectal carcinoma molecular
biomarkers (currently IHC testing for MLH1, MSH2, MSH6, and PMS2) in accordance with best laboratory
practices.
Strong recommendation
12. Laboratories must provide clinically appropriate turnaround times and optimal utilization of tissue
specimens by using appropriate techniques (eg, multiplexed assays) for clinically relevant molecular and
immunohistochemical biomarkers of colorectal cancer.
Expert consensus opinion
13. Molecular and IHC biomarker testing in colorectal carcinoma should be initiated in a timely fashion
based on the clinical scenario and in accordance with institutionally accepted practices.
Note: Test ordering can occur on a case-by-case basis or by policies established by the medical staff.
Expert consensus opinion
14. Laboratories should establish policies to ensure efficient allocation and utilization of tissue for
molecular testing, particularly in small specimens.
Expert consensus opinion
15. Members of the patient’s medical team, including pathologists, may initiate colorectal carcinoma
molecular biomarker test orders in accordance with institutionally accepted practices.
Expert consensus opinion
16. Laboratories that require send-out of tests for treatment predictive biomarkers should process and send
colorectal carcinoma specimens to reference molecular laboratories in a timely manner.
Note: It is suggested that a benchmark of 90% of specimens should be sent out within 3 working days.
Expert consensus opinion
17. Pathologists must evaluate candidate specimens for biomarker testing to ensure specimen adequacy,
taking into account tissue quality, quantity, and malignant tumor cell fraction. Specimen adequacy
findings should be documented in the patient report.
Expert consensus opinion
18. Laboratories should use colorectal carcinoma molecular biomarker testing methods that are able to
detect mutations in specimens with at least 5% mutant allele frequency, taking into account the
analytical sensitivity of the assay (limit of detection or LOD) and tumor enrichment (eg,
microdissection).
Note: It is recommended that the operational minimal neoplastic carcinoma cell content tested should
be set at least two times the assay’s LOD.
Expert consensus opinion
(table continues)
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Table 4 (continued )
Guideline Statement Strength of Recommendation
19. Colorectal carcinoma molecular biomarker results should be made available as promptly as feasible to
inform therapeutic decision making, both prognostic and predictive.
Note: It is suggested that a benchmark of 90% of reports be available within 10 working days from
date of receipt in the molecular diagnostics laboratory.
Expert consensus opinion
20. Colorectal carcinoma molecular biomarker testing reports should include a results and interpretation
section readily understandable by oncologists and pathologists. Appropriate Human Genome Variation
Society and Human Genome Organisation nomenclature must be used in conjunction with any historical
genetic designations.
Expert consensus opinion
21. Laboratories must incorporate colorectal carcinoma molecular biomarker testing methods into their
overall laboratory quality improvement program, establishing appropriate quality improvement monitors
as needed to ensure consistent performance in all steps of the testing and reporting process. In
particular, laboratories performing colorectal carcinoma molecular biomarker testing must participate in
formal proficiency testing programs, if available, or an alternative proficiency assurance activity.
Strong recommendation
EGFR, epidermal growth factor receptor; IHC, immunohistochemistry; MMR, mismatch repair; PTEN, phosphatase and tensin homolog.
ASCP/CAP/AMP/ASCO CRC Biomarker Guidelineapplication to be made by the physician in light of each
patient’s individual circumstances and preferences. The
ASCP, CAP, AMP, and ASCO make no warranty, express
or implied, regarding guidelines and statements and spe-
cifically exclude any warranties of merchantability and
fitness for a particular use or purpose. The ASCP, CAP,
AMP, and ASCO assume no responsibility for any injury or
damage to persons or property arising out of or related to
any use of this statement or for any errors or omissions.Results
A total of 4,197 studies met the search term requirements. A
total of 123 articles were included for data extraction.
Excluded articles were available as discussion or back-
ground references. The panel convened 14 times (11 tele-
conference webinars and three face-to-face meetings) from
July 27, 2013, through September 24, 2015, to develop the
scope, draft recommendations, review and respond to soli-
cited feedback, and assess the quality of evidence that
supports the final recommendations. Additional work was
completed via electronic mail. An open comment period
was held from March 30, 2015, through April 22, 2015,
during which draft recommendations were posted on the
AMP website. Twenty-one guideline statements had an
agreement ranging from 60% to 94% for each statement
from the open-comment period participants (refer to Out-
comes in the SDC for full details). The website received a
total of 248 comments. Teams of three to four expert panel
members were assigned three to five draft recommendations
to review all comments received and provide an overall
summary to the rest of the panel. Following panel discus-
sion and the final quality of evidence assessment, the panel
members determined whether to maintain the original draft
recommendation as is, revise it with minor language change,
or consider it as a major recommendation change. The
expert panel modified eight draft statements based on theThe Journal of Molecular Diagnostics - jmd.amjpathol.orgfeedback during the open-comment period and the consid-
ered judgment process. Resolution of all changes was ob-
tained by majority consensus of the panel using nominal
group technique (rounds of email discussion and multiple
edited recommendations) among the panel members. The
final recommendations were approved by the expert panel
with a formal vote. The panel considered the risks and
benefits throughout the whole process in their considered
judgment process. Formal cost analysis or cost-effectiveness
was not performed.
Each organization instituted a review process to approve
the guideline. The ASCP assigned the review of the
guideline to a Special Review Panel. For the CAP, an in-
dependent review panel (IRP) representing the Council on
Scientific Affairs was assembled to review and approve the
guideline. The IRP was masked to the expert panel and
vetted through the COI process. The AMP approval process
required the internal review of an independent panel led by
the Publications and Communications Committee Chair and
Executive Committee approval. The ASCO approval pro-
cess required the review and approval of the Clinical
Practice Guidelines Committee.Guideline Statements
1. Recommendation: Patients with CRC being considered
for anti-EGFR therapy must receive RAS mutational testing.
Mutational analysis should include KRAS and NRAS codons
12 and 13 of exon 2, 59 and 61 of exon 3, and 117 and 146
of exon 4 (“expanded” or “extended” RAS ) (Table 4).
Aberrant activation of EGFR signaling pathways in CRC
is primarily associated with activating mutations of genes in
the mitogen-activated protein kinase and phosphatidylino-
sitol-3-kinase (PI3K) pathways. Together, KRAS, NRAS,
and BRAF mutations have been reported to occur in more
than half of all CRC cases, and KRAS or NRAS and BRAF
mutations are inversely associated, with a small proportion193
Table 5 KRAS Clinical Practice Guidelines, Systematic Reviews, Meta-Analyses, Prospective Cohort Studies, and Retrospective Cohort
Studies
Author, Year
No. of Studies
(No. of Patients) Comparison Tests Used Codons Studied OS PFS ORR
CPGs, systematic reviews, and meta-analyses on KRAS mutationþ vs mutatione (n Z 30)
Petrelli et al,35
2013
SR: 12 studies
including
2,226 patients
with mCRC treated
with bevacizumab
Mutþ vs Mute NR NR Median, HR, 0.65;
95% CI, 0.46-
0.92; P < .05,
in favor of Mute
Median PFS, HR,
0.85; 95% CI,
0.74-0.98; P <
.05, in favor of
Mute
KRAS Mutþ:
48.3% vs KRAS
Mute: 54.8%
(OR, 1.42; 95%
CI, 1.05-1.92;
P < .05)
Mao et al,32
2013
SR: 10 studies
including 1,487
patients with mCRC
treated with
cetuximab
p.G13D vs codon 12
Mutþ
NR G13D, 12 HR, 0.52; 95% CI,
0.33-0.80,
P < .05, in favor
of G13D
PFS, HR, 0.54; 95%
CI, 0.36-0.81,
P < .05, in favor
of G13D
KRAS pG13D: 22%
KRAS 12: 16%
KRAS Mute: 44%
(pG13D vs 12: RR,
1.64; 95% CI,
1.13-2.38;
P < .05)
pG13D vs Mute:
RR, 0.54; CI,
0.38-0.77;
P < .05)
Jiang et al,27
2013
SR: 13 studies
including 1,174
patients with mCRC
treated with
cetuximab or
panitumumab
Increased vs not
increased EGRF
GCN
FISH, CISH, SISH,
qPCR
NR Increased GCN
associated with
improved OS
among patients
treated with
anti-EGFR mAbs
(HR, 0.62; 95%
CI, 0.50-0.77;
P < .05)
GCN associated
with improved
PFS (HR, 0.65;
95% CI, 0.47-
0.89; P < .05)
NR
Hoyle et al,25
2013
SR-HTA: 2 studies
including EGFR-
expressing mCRC
patients total with
cetuximab,
bevacizumab, or
panitumumab in
the second-line
and greater
Mutþ vs Mute NR NR Median, 9.5
months vs 4.8
months; HR,
0.55; 95% CI,
0.41-0.75, P <
.05, in favor of
cetuximab over
BSC in Mute
Panitumumab þ
BSC compared
with BSC alone
in Mute,
P Z ns
Median PFS, HR,
0.40; 95% CI,
0.30-0.54, P <
.05, third-line
cetuximab þ
BSC compared
with BSC alone
in Mute
Median PFS, HR,
0.45; 95% CI,
0.34-0.59,
P < .05,
panitumumab þ
BSC compared
with BSC alone
in Mute
KRAS Mute:
12.8%
KRAS Mutþ:
1.2%, P < .05,
cetuximab þ
BSC compared
with BSC alone
in Mute
KRAS Mute: 10%
KRAS mut: 0,
P < .05,
panitumumab
þ BSC
compared with
BSC alone in
Mute
Chen et al,21
2013
SR: 7 studies
including 2,802
patients with mCRC
Codon 13 Mutþ vs
other mutations
PCR, direct
sequencing
13, other Mutþ,
Mute
Median OS:
14.6 months,
codon 13
11.8 months
(other
mutation)
17.3 months,
Mute
Median PFS:
6.4 months, codon
13
4.1 months (other
mutation)
6.6 months, Mute
Codon 13 Mutþ
vs other
mutations: RR,
1.52 (95% CI,
1.10-2.09,
P < .05)
Codon 13 Mutþ
vs Mute: RR,
0.61 (95% CI,
0.45-0.83,
P < .05)
Zhou et al,16
2012
SR: 4 RCTs including
1,270 first-line
patients with mCRC
(all Mute)
Oxaliplatin CT 
anti-EGFR mAbs
Anti-EGFR þ CT vs CT
Mute only HR, 1.00; 95% CI,
0.88-1.13,
P Z ns
HR, 0.86; 95% CI,
0.71-1.04,
P Z ns
RR, 1.08; 95% CI,
0.86-1.36,
P Z ns
Zhang et al,41
2011
SR: 4 studies
including 2,912
patients with mCRC
Mutþ vs Mute NR NR Cetuximab þ CT vs
CT alone, Mute:
HR, 0.84; 95% CI,
0.64-1.11,
P Z ns
Cetuximab þ CT vs
Cetuximab þ CT vs
CT alone, Mute:
HR, 0.64; 95%
CI, 0.50-0.84, P
< .05, favors
þcetuximab
Cetuximab þ CT
vs CT alone:
RR, 1.93; 95%
CI, 1.14-3.26,
P < .05, favors
þcetuximab
(table continues)
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Author, Year
No. of Studies
(No. of Patients) Comparison Tests Used Codons Studied OS PFS ORR
CT alone,
mutation: HR,
1.03; 95% CI,
0.74-1.44,
P Z ns
Cetuximab þ CT vs
CT alone,
mutation: HR,
1.37; 95% CI,
0.81-2.31,
P Z ns
CetuximabþCT vs
CT alone, Mut
e: RR, 1.44;
95% CI, 1.20-
1.73, P < .05,
favors
þcetuximab
Yang et al,40
2012
SR: 19 studies
including 1,077
patients with mCRC
Mutþ vs Mute
GCNþ vs GCNe
FISH, qPCR,CISH Exon 20 No pooling due to
statistical
heterogeneity
No pooling due to
statistical
heterogeneity
No pooling due to
statistical
heterogeneity
Vale et al,39
2012
SR: 10 RCTs including
5,996 patients
with advanced CRC
Mutþ vs Mute NR NR NR
Third line, HR,
0.76; 95% CI,
0.62-0.92,
P < .05
First/second line,
PFS, HR, 0.83;
95% CI, 0.76-
0.90, P < .05
Third line, PFS, HR,
0.43; 95% CI,
0.35-0.52, P <
.05, in favor of
anti-EGFR MAbs
for Mute only
NR
Tsoukalas
et al,38
2012
SR: 13 studies
including 1,394
patients with CRC
Mutþ vs Mute
Response to
cetuximab vs no
response
NR NR NR NR NR
Ross et al,42
2012
SR: Six studies
including 2,526
patients with mCRC
Mutþ vs Mute
Antibody vs control
Sanger,
pyrosequencing,
PCR, ARMS,
Scorpion
NR NR NR NR
Ren et al,37
2012
SR: 23 studies
including 1,362
patients with
mutations
(w100% at
codons 12 and 13,
n Z 1 at codon
61)
Mutþ vs Mute d* 12, 13, 61 HR, 1.61; 95% CI,
1.19-2.18,
P < .05, in favor
of treatment in
Mute vs Mutþ
patients
NR NR
Petrelli et al,34
2012
SR: 4 RCTs including
484 Mute patients
with mCRC
Mutþ vs Mute
Cetuximab and/or
panitumumab þ CT
vs CT alone
NR NR P Z ns PFS, HR, 0.68,
P < .05, in favor
of adding
cetuximab and/
or panitumumab
to CT in Mute
patients
RR, 1.67, P <
.05, in favor
of adding
cetuximab
and/or
panitumumab
to CT in Mute
patients
Modest et al,14
2012
M-A: 3 trials
including 119
patients with mCRC
with codon 12
mutations vs other
mutations
Cetuximab  CT NR 12 P Z ns NR NR
Loupakis
et al,31
2012
SR: 8 trials including
6,609 patients
with mCRC
Mutþ vs Mute NR NR NR PFS, HR, 0.91; 95%
CI, 0.84-0.99; P
< .05, in favor
of adding anti-
EGFR MAbs to
CT in Mute
patients
(irinotecan
favoring CT,
P < .05)
RR, 1.17; 95% CI,
1.04-1.33; P <
.05, in favor of
KRAS Mute
Ku et al,28
2012
SR: 2 RCTs including
261 patients with
mCRC
Cetuximab þ 5FU
with oxaliplatin vs
irinotecan
Mutþ vs Mute
NR NR No pooling
performed in
this comparison
AIO trial, P Z ns
No pooling
performed in
this comparison
AIO trial, P Z ns
NR
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Author, Year
No. of Studies
(No. of Patients) Comparison Tests Used Codons Studied OS PFS ORR
CECOG trial, P <
.05 in favor of
cetuximab þ
FOLFOX in Mute
patients
CECOG trial, P Z
ns in favor of
cetuximab þ
FOLFOX in Mute
patients
Petrelli et al,15
2011
SR: 7 trials including
5,212 patients
with advanced
CRC, KRAS Mute
only
Cetuximab or
panitumumab þ
CT vs BSC
NR NR HR, 0.84; 95% CI,
0.73-0.98,
P < .05, in favor
of anti-EGFR
mAbs vs no
mAbs in Mut
epatients
PFS, HR, 0.65; 95%
CI 0.51-0.83, P
< .05, in favor
of anti-EGFR
mAbs vs no
mAbs in Mute
patients
RR, 1.69; 95% CI,
1.20-2.38;
P < .05, in
favor of anti-
EGFR
Mao et al,33
2012
SR: 13 studies
including 576
patients with
mCRC, all KRAS Mut
etreated with
anti-EGFR MAbs
Mutþ vs Mute Direct sequencing,
survey analysis,
alleic
discrimination,
Sanger
PIK3CA exon 9,
20
HR, 3.29; 95% CI,
1.60-6.74;
P < .05
PFS, HR, 2.52; 95%
CI, 1.33-4.78,
P < .05, PIK3CA
exon 20
mutations
associated with
significantly
shorter PFS
duration
RR, 0.25; 95% CI,
0.05-1.19;
P < .05,
PIK3CA exon
20 mutations
associated
with lower ORR
Lin et al,29
2011
SR: 8 studies
including 5,325
patients with
advanced CRC
Mutþ vs Mute NR NR P Z ns PFS, HR, 0.66; 95%
CI, 0.53-0.82,
P < .05, in favor
of adding anti-
EGFR to CT in
Mute patients
NR
Ibrahim
et al,13
2011
SR: 4 studies
including 2,115
patients with mCRC
with Mute KRAS
Panitumumab-based
treatment vs
control
NR NR P Z ns PFS, HR, 0.58; 95%
CI, 0.36-0.93; P
< .05, in favor
of adding
panitumumab to
CT in Mute
patients
OR, 1.08; 95% CI,
0.75-1.58;
P Z ns
Dahabreh
et al,22
2011
SR: 29 poolable
studies including
5,032 patients
with mCRC treated
with anti-EGFR
mAbs
Mutþ vs Mute
Mutþ vs Mute
Cetuximab or
panitumumab þ CT
vs CT alone
NR NR HR, 1.30; 95%
CI, 0.95-1.78,
PZ ns in Mute
patients
PFS, HR, 2.22; 95%
CI, 1.74-2.84,
P < .05, in favor
of anti-EGFR þ
CT in Mute
patients only
Positive
likelihood
ratio, 7.35
(95% CI, 3.72-
14.50)
Negative
likelihood
ratio, 0.55
(95% CI, 0.49-
0.61)
KRAS mutations
associated
with higher
likelihood of
response
failure
Baas et al,20
2011
SR: 21 studies
including w1,213
patients with mCRC
(one study, N Z
NR)
Concordance between
KRAS Mutþ/Mute
between primary
and metastases
Sequencing,
pyrosequencing,
PCR-RFLP, SSCP,
AS-PCR, ASO
KRAS, PIK3CA,
BRAF, or of loss
of PTEN
NR NR NR
Adelstein
et al,18
2011
SR: 11 studies
including 8,924
patients with mCRC
treated with anti-
EGFR mAbs
Mutþ vs Mute
Cetuximab or
panitumumab þ CT
vs CT alone
NR 12, 13, 61 NR PFS, HR, 0.80; 95%
CI, 0.64-0.99,
P < .05, in favor
of anti-EGFR
mAbs in Mute
patients
RD, 15%; 95% CI,
8%-22%,
P < .05, in
favor of KRAS
Mute þ anti-
EGFR treatment
(table continues)
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Author, Year
No. of Studies
(No. of Patients) Comparison Tests Used Codons Studied OS PFS ORR
Qiu et al,36
2010
SR: 22 studies
including 2,188
patients with mCRC
Mutþ vs Mute
Cetuximab þ CT vs CT
alone
DS, surveyor
analysis, qPCR,
AD, melting
curve analysis
Exon 1, 2 Median OS, 6.9 vs
13.5 months,
HR, 2.17; 95%
CI, 1.72-2.74,
P < .05, longer
median survival
shown in Mute
patients who
received anti-
EGFR mAbs þ CT
Median PFS, 3.0 vs
5.8 months, HR,
1.94; 95% CI,
1.62-2.33; P <
.05, longer
median PFS
shown in Mut
epatients who
received anti-
EGFR mAbs þ CT
KRAS Mute: 39%
KRAS Mutþ: 14%
RR, 0.24; 95% CI,
0.16-0.38,
P < .05
Health
Quality Ontario,24
2010
SR: 14 observational
studies in patients
with advanced CRC
Mutþ vs Mute
Cetuximab or
panitumumab þ CT
vs CT alone
NR NR Mean OS, MD,
e4.11; 95% CI,
e5.60 toe2.62,
P < .05, longer
survival detected
in Mute patients
treated with
cetuximab
þirinotecan
Mean PFS, MD,Z
e3.32; 95% CI,
e4.86 toe1.78,
P < .05, longer
duration
detected in Mut
e patients
treated with
cetuximabþ
irinotecan
NR
Ibrahim
et al,26
2010
SR: 10 studies
including 2,703
patients with mCRC
Mutþ vs Mute
Cetuximab þ CT vs CT
alone
NR NR P < .05, in favor of
treatment with
cetuximab þ CT
in Mute
patients
PFS, P < .05, in
favor of
treatment with
cetuximab þ CT
in Mute
patients
OR, 2.10; 95% CI,
1.42-3.10,
P < .05
De Roock
et al,23
2010
MA: 7 studies
including 774
patients with mCRC
who received
cetuximab-based
treatment  CT
pG13D vs other
mutation
NR pG13D, 13 Median (95% CI):
pG13D: 7.6 months
(5.7-20.5)
Other mutations:
5.7 months
(4.9-6.8)
Mute: 10.1
months
(9.4-11.3)
P < .05, pG13D
superior to
other mutations
Median (95% CI)
PFS:
pG13D: 4.0 months
(1.9-6.2)
Other mutations:
1.9 months
(1.8-2.8)
Mute: 4.2 months
(3.9-5.4)
P < .05, pG13D
superior to
other mutations
NR
Allegra et al,19
2009
SR: 5 RCTs including
627 patients with
mCRC and 5 single-
arm studies
including 247
patients
Mutþ vs Mute PCR, direct
sequencing
12, 13 No pooling was
performed
No pooling was
performed
No pooling was
performed
Linardou
et al,30
2008
SR: 8 studies
including 817
patients with mCRC
(306 with KRAS
mutations)
Mutþ vs Mute NR 12, 13, 61 NR NR
Sorich et al,12
2015
SR: 9 RCTs including
5,948 patients
with mCRC
Mutþ vs Mute
Anti-EGFR mAb
treatment effect
size between RAS
subgroups,
including Mutþ vs
Mute
Bidirectional
Sanger
sequencing,
pyrosequencing,
MALDI-TOF
analysis, and
WAVE-based
Surveyor
analysis
KRAS/NRAS 12,
13, 59, 61,
117, 146
RAS Mute vs RAS
Mutþ:
HR, 0.72 (95% CI,
0.56-0.92; P <
.01) RAS Mute
superior
KRAS exon 2
mutant vs new
RAS mutant:
P Z ns
RAS Mute, anti-
EGFR vs no anti-
EGFR: HR, 0.87
RAS Mute vs RAS
Mutþ:
HR, 0.60 (95% CI,
0.48-0.76; P <
.001) RAS Mute
superior
KRAS exon 2
mutant vs new
RAS mutant:
P Z ns
RAS Mute, anti-
EGFR vs no anti-
EGFR: HR, 0.62
NR
(table continues)
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Author, Year
No. of Studies
(No. of Patients) Comparison Tests Used Codons Studied OS PFS ORR
(95% CI, 0.77-
0.99; P < .04)
KRAS exon 2 Mute,
anti-EGFR vs no
anti-EGFR: HR,
0.90 (95% CI,
0.83-0.98;
P Z ns)
Any RAS mutant,
anti-EGFR vs no
anti-EGFR: HR,
1.08 (95% CI,
0.97-1.21;
P Z ns)
KRAS exon 2
mutant, anti-
EGFR vs no anti-
EGFR: HR, 1.05
(95% CI, 0.95-
1.17; P Z ns)
(95% CI, 0.50-
0.76; P < .001)
KRAS exon 2 Mute,
anti-EGFR vs no
anti-EGFR: HR,
0.68 (95% CI,
0.58-0.80;
P < .001)
Any RAS mutant,
anti-EGFR vs no
anti-EGFR: HR,
1.12 (95% CI,
0.94-1.34;
P Z ns)
KRAS exon 2
mutant, anti-
EGFR vs no anti-
EGFR: HR, 1.14
(95% CI, 0.95-
1.36; P Z ns)
Randomized controlled trials (n Z 1)
Douillard
et al,44
2013
RCT: reanalysis of
PRIME trial (NCT:
00364013) data,
including 1,060
patients
RAS Mut and
FOLFOX4  anti-
EGFR mAb
PCR, Sanger,
Surveyor
KRAS/NRAS 12,
13, 61, 117,
146
Mut and anti-
EGFR mAb:
26 months vs 20.2
months
HR, 0.78 (95% CI,
0.62-0.99; P <
.05) in favor of
Mute and þ
anti-EGFR mAb
Mut and anti-
EGFR mAb:
10.1 months vs 7.9
months
HR, 0.72 (95% CI,
0.58-0.90; P <
.05) in favor of
Mute and þ
anti-EGFR mAb
NR
Prospective cohort studies (n Z 1)
Etienne-
Grimaldi
et al,45
2014
251 patients KRAS Mutþ vs KRAS
Mute
NR KRAS 12, 13 NR RR, 2.40 (95% CI,
1.27-4.55; P <
.05), RFS
shorter in KRAS
Mutþ patients
with stage III
tumors
NR
Retrospective cohort studies (n Z 1)
Bando et al,43
2013
82 samples from 376
patients
All Mute vs KRAS 12,
13 vs KRAS 61, 146
Luminex xMAP vs
DS
(concordance
rate 100%)
KRAS 12,13,
61,146
All Mute: 13.8
months (9.2-
18.4) vs KRAS
Mutþ: 8.2
months (5.7-
10.7; P < .05)
All Mute: 6.1
months (3.1-
9.2) vs KRAS
Mutþ: 2.7
months (1.2-
4.2; P < .05)
All Mute: 38.8%
vs KRAS Mutþ:
4.8%, P < .05
AD, allelic discrimination-PCR; AIO, German AIO colorectal study group; ARMS, amplification refractory mutation system; AS-PCR, allele-specific polymerase
chain reaction; ASO, allele-specific oligonucleotide; BRAF, proto-oncogene B-Raf/v-Raf murine sarcoma viral oncogene homolog B; BSC, best supportive care;
CECOG, Central European Cooperative Oncology Group; CI, confidence interval; CISH, chromogenic in situ hybridization; CPG, clinical practice guideline; CRC,
colorectal cancer; CT, chemotherapy; DS, direct sequencing; EGFR, epidermal growth factor receptor; FOLFOX4, folacin, 4-fluorouracil, oxaliplatin; FISH,
fluorescence in situ hybridization; FOLFOX, folinic acid (leucovorin calcium), 5-fluorouracil, and oxaliplatin; 5FU, fluorouracil; GCN, gene copy number; HR,
hazard ratio; HTA, health technology assessment; KRAS, Kirsten rat sarcoma viral oncogene homolog; M-A, meta-analysis; MALDI-TOF, matrix-assisted laser
desorption/ionization-time of flight; mCRC, metastatic colorectal cancer; MD, mean difference; mAbs, monoclonal antibodies; Mute, mutation negative or wild
type; Mutþ, mutation positive; NR, not reported; NRAS, neuroblastoma RAS viral (v-ras) oncogene homolog; ns, nonsignificant; OR, odds ratio; ORR, objective
response rate; OS, overall survival; PCR, polymerase chain reaction; PCR-RFLP, polymerase chain reactionerestriction fragment length polymorphism; PFS,
progression-free survival; PIK3CA, phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha; PRIME, Panitumumab Randomized Control Trial in
Combination with Chemotherapy for Metastatic Colorectal Cancer to Determine Efficacy; PTEN, phosphatase and tensin homolog; qPCR, quantitative polymerase
chain reaction; RCT, randomized controlled trial; RAS, rat sarcoma viral oncogene homolog; RD, risk difference; RFS, recurrence-free survival; RR, response rate;
SISH, silver in situ hybridization; SR, systematic review; SSCP, single-strand conformation polymorphism; xMAP, multiplex assay.
*Tests used by Ren et al37: hybridization, PCR, direct sequencing, topographic genotyping, AS-PCR, tissue transglutaminase enzyme, high-performance liquid
chromatography, pyrosequencing, capillary sequencing.
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mutations.3,12
Cetuximab and panitumumab are antibodies that bind to
the extracellular domain of EGFR, blocking the binding of
EGF and other EGFR endogenous ligands, thereby blocking
EGFR signaling. Earlier studies reported the effects of anti-
EGFR antibody treatment independent of KRAS status.13-16
However, it was later reported that targeted EGFR therapies
with cetuximab or panitumumab improve PFS and OS in
patients with metastatic CRCwith wild-typeKRAS but not for
patients with mutatedKRAS.2,3,17 In these earlier studies, only
mutations of KRAS exon 2 were considered. Based on the
available clinical trial data in 2009, the ASCO recommended
that patients with metastatic CRCwho are candidates for anti-
EGFR antibody therapy should have their tumor tested for
KRAS mutations in a Clinical Laboratory Improvements
Amendments ’88 (CLIA)eaccredited laboratory.2
A large body of evidence was available to guide the
recommendation in the current guideline for RAS testing in
colorectal cancers (Table 5 and Supplemental Table 14; all
supplemental materials can be found at http://dx.doi.org/10.
1016/j.jmoldx.2016.11.001). From 2008 to 2015, there were
311 primary studies that included 74,546 patients and re-
ported treatment outcomes for patients with RAS mutations
compared with nonmutated/wild type.12-16,18-45 The most
common comparison of anti-EGFR antibody treatment
outcomes was between KRAS mutation vs KRAS non-
mutated/wild type.18-20,22,24-26,28-31,33-42 Some studies also
compared the effects of adding an anti-EGFR inhibitor to
KRAS nonmutated/wild-type patients vs chemotherapy
alone.18,22,24,26,28,36-38 A few studies reported anti-EGFR
antibody treatment outcomes for the following compari-
sons: KRAS G13D vs codon 12 mutations,32 KRAS codon
13 mutations vs other mutations,21 and G13D vs other exon
2 mutations.23
The reported anti-EGFR therapy outcomes in these
studies were pooled survival,13-16,21-27,29,32-37,39,41 pooled
PFS,13,15,16,18,21-27,29,31-36,39,41 and pooled objective
response rate (ORR).13,15,16,18,21,22,25,26,30-36,41 Thirteen
studies reported significant differences between compara-
tors.15,21,23-27,32,33,35-37,39 The systematic review literature
of data on anti-EGFR therapy outcomes is presented in
Supplemental Table 14. Five of these studies detected a
significant pooled survival advantage of antieEGFR-treated
patients for KRAS nonmutated/wild type compared with
KRAS mutation.21,33,35,37,39 Three studies detected an
advantage for patients with nonmutated tumors given anti-
EGFR treatment compared with KRAS mutation-positive
patients given chemotherapy alone.24,26,36 Twenty of the
included studies pooled PFS,13,15,16,18,21-27,29,31-36,39,41 with
19 reporting significant differences between compara-
tors.13,15,18,21-27,29,31-36,39,41 Fourteen papers detected a
significant PFS advantage for adding an anti-EGFR inhibi-
tor to chemotherapy for KRAS nonmutated/wild-type pa-
tients compared with chemotherapy alone.13,15,18,22,24-
26,29,31,33,34,36,39,41 Sixteen of the included papers pooledThe Journal of Molecular Diagnostics - jmd.amjpathol.orgORR,13,15,16,18,21,22,25,26,30-36,41 with 14 reporting significant
differences between comparators.15,18,21,22,25,26,30-36,41
Eight studies detected ORR advantages for adding an anti-
EGFR inhibitor to chemotherapy for patients with
nonmutated/wild-type tumors compared with chemotherapy
alone,18,25,26,30,33,34,36,41 and four detected an ORR advan-
tage for KRAS nonmutated/wild-type patients over mutation
patients.22,31,32,35 Survival advantages (OS and PFS, ORR)
for G13D mutations over codon 12 and G13D over other
mutations were reported in two studies23,32 and codon 13
over other KRAS mutations.21
Recent studies showed conclusive evidence that in addi-
tion to mutations in KRAS exon 2, other RAS mutations in
KRAS exons 3 and 4 and NRAS exons 2, 3, and 4 were also
associated with nonresponse of metastatic CRC to anti-
EGFR monoclonal antibody therapy.12,44,46 Douillard
et al44 published a reanalysis of the Panitumumab Ran-
domized Control Trial in Combination with Chemotherapy
for Metastatic Colorectal Cancer to Determine Efficacy
(PRIME) trial, reporting that patients with any RAS muta-
tions were associated with inferior PFS and OS with
panitumumab-FOLFOX4 treatment, which was consistent
with the findings previously reported for patients with KRAS
mutations in exon 2. Subsequently, a meta-analysis of nine
randomized clinical trials provided further evidence that not
all KRAS exon 2 nonmutated/wild-type tumors benefit from
anti-EGFR monoclonal antibody treatment in metastatic
CRC.12 Patients with colorectal cancers that are KRAS exon
2 nonmutated/wild type but harbor RAS mutations in KRAS
exons 3 and 4 or NRAS exons 2, 3, and 4 also have
significantly inferior anti-EGFR treatment outcomes benefit
compared with those without any RAS mutations (Table 5
and Table 6). RAS mutations occur mostly at exon 2, fol-
lowed by mutations in exons 3 and 4 (Table 7). The results
suggest that “extended” or “expanded” RAS mutation testing
(KRAS exons 2, 3, and 4 and NRAS exons 2, 3, and 4) must
be performed before the administration of an anti-EGFR
monoclonal antibody therapy.12 In summary, current evi-
dence indicates that both cetuximab and panitumumab
should only be prescribed for patients with metastatic CRCs
that are nonmutated/wild type for all known RAS-activating
mutations.12
This recommendation is supported by 34 studies,12-16,18-
45,47 comprising 29 systematic studies,12,13,15,16,18-22,24-
42,47 two meta-analyses,14,23 one randomized controlled
trial,44 one prospective cohort study,45 and one retrospective
cohort study.43
Of the 29 systematic reviews,12,13,15,16,18-22,24-42,47 only
three reported using a multidisciplinary panel,19,25,30 and
only one reported taking patient preferences into account,37
although 13 examined important patient sub-
types.12,15,16,18,21,22,24,27,30,33,37,39,40 All but one had well-
described and reported methods sections.42 Seven did not
report on conflict of interest.13,15,16,34,38,41,42 Only nine
rated the quality of the included evidence, and these same
nine were the only ones that reported on the strength of the199
Table 6 Outcomes of RAS Mutations and Anti-EGFR Therapy12
Characteristic
Overall Survival Progression-Free Survival
HR (95% CI) P Value HR (95% CI) P Value
RAS nm vs RAS mutation, RAS nm superior 0.72 (0.56-0.92) <.01 0.60 (0.48-0.76) <.001
KRAS exon 2 mutant vs new RAS mutant ns ns
KRAS nm exon 2, anti-EGFR vs no anti-EGFR 0.90 (0.83-0.98) ns 0.68 (0.58-0.80) <.001
KRAS exon 2 mutant, anti-EGFR vs no anti-EGFR 1.05 (0.95-1.17) ns 1.14 (0.95-1.36) ns
RAS nm, anti-EGFR vs no anti-EGFR 0.87 (0.77-0.99) <.04 0.62 (0.50-0.76) <.001
Any RAS mutant, anti-EGFR vs no anti-EGFR 1.08 (0.97-1.21) ns 1.12 (0.94-1.34) ns
CI, confidence interval; EGFR, EGFR, epidermal growth factor receptor; HR, hazard ratio; KRAS, Kirsten rat sarcoma viral oncogene homolog; nm, nonmutated;
ns, nonsignificant; RAS, rat sarcoma viral oncogene homolog.
Sepulveda et alincluded evidence.16,18,21,22,24,25,32,37,39 None of the studies
included a plan for updating. None of the systematic re-
views reported industry funding, two reported no fund-
ing,16,31 and 11 did not report on the source of funding, if
any.13,15,26,32,34-36,38,41,42,47 Two of these systematic re-
views were deemed to have a low risk of bias,24,37 14 were
deemed to have a low to moderate risk of
bias,12,16,18,19,21,22,25,27,29,30,32,35,39,47 12 were deemed to
have a moderate risk of bias,13,15,20,26,28,31,33,34,36,38,40,41
and one was deemed to have a high risk of bias.42
Of the two meta-analyses obtained,14,23 both had well-
reported and reproducible methods sections, both
described the planned pooling a priori, and both discussed
the limitations of their analyses. Neither was based on a
systematic review of the literature, and neither did a
quality assessment of the included studies. One reported
nonindustry funding,23 and the other reported industryTable 7 Prevalence of New RAS Mutations Across Studies*
Study New RAS Total,y % KRAS Exon 3,y % KRAS Exo
Codons 59, 61 Codons 1
OPUS 26.3 5.9 9.3
PICCOLO 9.8 NRz 3.7x
20020408 17.6 4.8z 5.0
20050181 20.5 4.6 7.9
PRIME 17.4 3.7z 5.6
FIRE-3 16.0 4.3z 4.9x
PEAK 20.1 4.1 7.7
COIN 8.4 2.1c NE
CRYSTAL 14.7 3.3 5.6
Summary (95% CI)** 19.9 (16.7-23.4) 4.3 (3.3-5.5) 6.7 (5.7
CI, confidence interval; COIN, Combination Chemotherapy With or Without Cetu
Cancer Trial; CRYSTAL, Cetuximab Combined with Irinotecan in First-Line Therapy
(FOLFIRI) Plus Cetuximab vs FOLFIRI Plus Bevacizumab in First-Line Treatment
evaluated but not reported; OPUS, Effect of Roflumilast on Exacerbation Rate in P
PEAK, Panitumumab Plus mFOLFOX6 vs Bevacizumab Plus mFOLFOX6 for First-Line
Kirsten Rat Sarcoma-2 Virus (KRAS) Tumors Trial; PICCOLO, Panitumumab and Irin
Resistant Advanced Colorectal Cancer Trial; PRIME, Panitumumab Randomized Tr
Determine Efficacy Trial.
*Modified from Sorich et al12 by permission of Oxford University Press on beha
yNew RAS mutations are reported as a proportion of the KRAS exon 2 nonmuta
zKRAS and NRAS codon 59 mutation was not evaluated.
xKRAS codon 117 mutation was not evaluated.
{Exon 3 codon 61 mutations in addition to the exon 2 mutations.
kOnly NRAS mutation G12C evaluated.
**Random-effects meta-analysis summary estimates.
200funding.14 One was deemed to have a low to moderate risk
of bias,23 and the other was deemed to have a moderate
risk of bias.14
The single randomized controlled trial did not report on any
details of the randomization, including blinding, the expected
effect size and power calculation, and the length of follow-
up.44 It did report on differences in baseline patient charac-
teristics. This trial did report at least partial industry funding
and was deemed to have a low to moderate risk of bias.44
The single prospective cohort study reported a balance
between treatment and assessment groups, reported on
baseline characteristics, and made adjustments in the anal-
ysis when differences were found.45 It reported nonindustry
funding and was deemed to have a low risk of bias.45
The single retrospective cohort study reported that the
treatment and assessment groups were in balance and also
reported on baseline patient characteristics.43 It did notn 4,y % NRAS Exon 2,y % NRAS Exon 3,y % NRAS Exon 4,y %
17, 146 Codons 12, 13 Codons 59, 61 Codons 117, 146
6.8 5.1 0.8
6.3{ NRz NE
4.2 3.0z 1.1
2.3 5.8 0.0
3.4 4.1z 0.0
3.8 2.0z 0.0
5.4 5.9 0.0
0.9k 3.0z NE
3.5 2.8 0.9
-7.9) 3.8 (3.0-4.8) 4.8 (3.4-6.8) 0.5 (0.2-1.2)
ximab as First-Line Therapy in Treating Patients With Metastatic Colorectal
for Metastatic Colorectal Cancer Trial; FIRE-3, Folinic Acid and Irinotecan
Colorectal Cancer (CRC) Trial; NA, not applicable; NE, not evaluated; NR,
atients With Chronic Obstructive Pulmonary Disease (BY217/M2-111) Trial;
Treatment of Metastatic Colorectal Cancer (mCRC) Patients With Wild-Type
otecan vs Irinotecan Alone for Patients With KRAS Wild-Type, Fluorouracil-
ial in Combination With Chemotherapy for Metastatic Colorectal Cancer to
lf of the European Society for Medical Oncology.
ted/wild-type group.
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ASCP/CAP/AMP/ASCO CRC Biomarker Guidelinereport that adjustments were made in the analysis to account
for differences, where differences were found. This study
reported nonindustry funding and was deemed to have a low
risk of bias.43
All of the evidence that supported this recommendation
was assessed, and none was found to have methodologic
flaws that would raise concerns about their findings.
2a. Recommendation: BRAF p.V600 [BRAF c.1799
(p.V600)] position mutational analysis should be performed
in CRC tissue in selected patients with colorectal carcinoma
for prognostic stratification.
BRAF activating mutations occur in about 8% of
advanced disease patients with CRC47,48 and in approxi-
mately 14% of patients with localized stage II and III
CRC.8,49 As such, mutations in BRAF constitute a sub-
stantial subset of patients with CRC. The key questions
related to BRAF mutations are whether patients whose
cancers carry a BRAF mutation have a poorer outcome
compared with BRAF mutation-negative tumors and
whether the presence of a mutation predicts benefit from or
lack thereof to anti-EGFR therapy.
Four systematic reviews20,50-52 and three systematic re-
views that included meta-analyses47,48,53 pertaining to the
prognostic and predictive value of BRAF mutations in
patients with CRC were identified through our systematic
review process (Table 8 and Supplemental Table 14). These
studies revealed that patients with advanced CRC who
possess a BRAF mutation have significantly poorer out-
comes as measured by PFS and OS and have a decreased
response rate to anti-EGFR therapy relative to those with
nonmutated BRAF. Poorer OS was also demonstrated for
those patients with earlier stage II and III CRC having a
BRAF mutation8,54; however, the poorer outcome appears to
be primarily the result of decreased OS after relapse in these
patients rather than a harbinger of an increased rate of
relapse. Finally, while outcomes in advanced disease pa-
tients with BRAF mutations were poorer relative to non-
mutation patients, the data were consistent with a modest
beneficial impact from the use of anti-EGFR agents relative
to those patients whose tumors contained a RAS mutation.55
In summary, patients with CRC that contains a BRAF
mutation have a worse outcome relative to nonmutation
patients. Selected patients for BRAF mutation testing
include patients with metastatic disease, since these patients
have particularly poor outcomes. It is important to know the
BRAF c.1799 (p.V600) mutation status of a patient’s CRC
since standard therapy is not adequate for patients with
metastatic disease and BRAF mutation. For these patients,
some studies suggest the use of FOLFIRINOX [folinic acid
(leucovorin calcium), 5-fluorouracil, irinotecan hydrochlo-
ride, and oxaliplatin] as first-line therapy, followed by
enrollment in a clinical trial.56 Furthermore, early clinical
trials data suggest that the combination of a BRAF
plus EGFR inhibitor appears to be effective in this popu-
lation.57-59 Data in support of molecular testing for BRAFThe Journal of Molecular Diagnostics - jmd.amjpathol.orgc.1799 (p.V600) mutations in CRC continue to emerge from
clinical trials. A recent publication of the PETACC-8
(oxaliplatin, fluorouracil, and leucovorin with or without
cetuximab in patients with resected stage III colon cancer
randomised phase 3) trial reported that trials in the adjuvant
setting should consider mismatch repair, BRAF, and KRAS
status for stratification, since BRAF p.V600 and KRAS
mutations were associated with shorter DFS and OS in pa-
tients with microsatellite-stable colon cancer but not in those
with tumors with MSI.60,61
This recommendation is supported by seven systematic
reviews,20,47,48,50-53 three of which included meta-anal-
ysis.47,48,53 None of the systematic reviews reported the
composition of their panel, so multidisciplinary panel rep-
resentation could not be confirmed, and none reported pa-
tient representation on the panel. All but the systematic
review reported by Baas et al20 reported examining impor-
tant patient subgroups. All of the systematic reviews re-
ported well-described and reproducible methods. Three did
not report how conflicts of interest were managed and re-
ported on.47,51,53 Only two reported on a quality assessment
of the included literature,48,50 and only one rated the
strength of the evidence.50 None reported a plan for
updating. While none of the systematic reviews reported
industry funding, one study did not report any funding
support.47 Overall, the risk of bias assessment for this body
of evidence ranged from low48,50 to moderate,20,51,53 and
none were found to have methodologic flaws that would
raise concerns about their findings.
2b. Recommendation: BRAF p.V600 mutational anal-
ysis should be performed in dMMR tumors with loss of
MLH1 to evaluate for Lynch syndrome risk. Presence of a
BRAF mutation strongly favors a sporadic pathogenesis.
The absence of BRAF mutation does not exclude risk of
Lynch syndrome.
dMMR occurs via several mechanisms. In sporadic CRC,
dMMR is most frequently caused by epigenetic silencing
through CpG methylation primarily of MLH1, with few
cases resulting from somatic mutation of one of the MMR
genes. In Lynch syndrome CRC, the underlying mechanism
is usually a germline mutation of one of the four (MLH1,
MSH2, MSH6, and PMS2) mismatch repair genes and, in
rare patients, a deletion involving EPCAM (epithelial cell
adhesion molecule), a gene adjacent to MSH2, that leads to
epigenetic inactivation of the MSH2 gene. dMMR occurs in
15% to 20% of all colorectal cancers, and of these, about
three-fourths are due to MLH1 epigenetic silencing.5,62
dMMR underlies widespread mutations in the genome and
MSI. BRAF p.V600 mutations rarely occur in patients with
germline-based dMMR but have been reported in up to
three-fourths of those with epigenetic MMR gene silencing
(Table 8 and Table 9). Thus, testing for BRAF mutations
serves as a means for distinguishing germline from epige-
netic dMMR, particularly in those cases where the dMMR is
the result of epigenetic silencing of MLH1. For tumors with201
Table 8 BRAF Clinical Practice Guidelines, Systematic Reviews, Meta-Analyses, Prospective Cohort Studies, and Retrospective Cohort
Studies
Author, Year Study Type and Evidence Comparison Tests Used
CPGs, systematic reviews, and meta-analyses (n Z 8)
Parsons et al,52 2012 SR: 36 studies including 4,562 CRC
tumors (BRAF ), 43 studies including
2,975 CRC tumors (MLH1)
Correlation study NR
Mao et al,51 2011 SR: 11 studies including 1,046
patients with mCRC
Mutþ vs Mute NR
Lin et al,50 2011 SR: 1 study of 649 patients with
mCRC, all KRAS Mute; 6.5% were
BRAF Mutþ
Mutþ vs Mute NR
Baas et al,20 2011 SR: 7 studies including 538 patients
with mCRC
Mutþ vs Mute Sequencing, pyrosequencing
Cui et al,53 2014 SR: 4 studies including 1,245 patients Mutþ vs Mute
CT  anti-EGFR mAbs
PCR
Yang et al,71 2013 SR: 17 studies (patients, n Z NR) Mutþ vs Mute d*
Yuan et al,48 2013 SR: 21 studies including 5,229
patients
Mutþ vs Mute NR
Xu et al,47 2013 SR: 19 studies including 2,875
patients
Mutþ vs Mute NR
Prospective cohort studies (n Z 1)
Etienne-Grimaldi et al,45 2014 251 patients Mutþ vs Mute NR
Retrospective cohort studies (n Z 1)
Bando et al,43 2013 82 samples from 376 patients All Mut- vs BRAF Mutþ and
PIK3CA Mute
Luminex xMAP vs DS
(concordance rate 100%)
(table continues)
BRAF, proto-oncogene B-Raf/v-Raf murine sarcoma viral oncogene homolog B; CI, confidence interval; CPG, clinical practice guideline; CRC, colorectal
cancer; CT, chemotherapy; DS, direct sequencing; EGFR, epidermal growth factor receptor; HR, hazard ratio; KRAS, Kirsten rat sarcoma viral oncogene
homolog; mAbs, monoclonal antibodies; mCRC, metastatic colorectal cancer; MLH1, mutL homolog 1; Mute, mutation negative or wild type; Mutþ,
mutation positive; NR, not reported; ns, nonsignificant; ORR, objective response rate; OS, overall survival; PCR, polymerase chain reaction; PFS,
progression-free survival; PIK3CA, phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha; RR, response rate; RFS, recurrence-free
survival; SR, systematic review; xMAP, multiplex assay.
*Yang et al71: adenovirus-PCR pyrosequencing, allele-specific PCR, DS, PCR amplification, quantitative PCR, Sanger, real-time PCR, genotypingþDS, PCR
clamping, melting curve analysis, DNA sequencing, and Taqman single-nucleotide polymorphism assay.
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Table 8 (continued)
Codons Studied OS PFS ORR
BRAF p.V600E, MLH1 NR NR NR
V600E NR NR BRAF Mutþ: 0 BRAF Mute: 36.3%;
P < .05; RR, 0.14; 95% CI, 0.04-
0.53
V600E Shorter duration in BRAF Mutþ
patients, difference 28 weeks,
P < .05
PFS, shorter duration in BRAF
Mutþ patients, difference 18
weeks, P < .05
NR
V600E NR NR NR
V600E NR NR Mutþ vs Mute (all KRAS Mute): RR,
0.43 (95% CI, 0.16-0.75; P < .05)
in favor of Mute
Mut  vs CT  anti-EGFR mAbs (all
KRAS Mute): RR, 0.38 (95% CI,
0.20-0.73; P < .05) in favor of
Mute
Mutþ and CT  anti-EGFR mAbs;
P Z ns
Mute and KRAS Mute and CT 
anti-EGFR mAbs: RR, 1.48 (95%
CI, 1.28-1.71; P < .05) in favor of
BRAF Mute with CT þ anti-EGFR
mAbs
V600E, 599, 466, 469 (7 studies)
BRAF Mut : HR, 2.74 (95% CI,
1.79-4.19; P < .05) in favor of
BRAF Mute
(8 studies)
BRAF Mut :
HR, 2.59 (1.67, 4.03; P < .05) in
favor of BRAF Mute
BRAF Mute: 46.4%
BRAF Mut: 18.5%
P < .05 in favor of BRAF Mute
V600E HR, 0.35 (95% CI, 0.29-0.42;
P < .05) in favor of BRAF Mute
HR, 0.38 (95% CI, 0.29-0.51;
P < .05) in favor of BRAF Mute
RR, 0.31 (95% CI, 0.18-0.53;
P < .05) in favor of BRAF and
KRAS Mute
V600E, K601E (1 study),
D549C (1 study)
HR, 2.85 (95% CI, 2.31-3.52;
P < .05) in favor of BRAF Mute
HR, 2.98 (95% CI, 2.07-4.27;
P < .05) in favor of BRAF Mute
ORR, 0.58 (95% CI, 0.35-0.94;
P < .05) in favor of BRAF Mute
BRAF p.V600E NR Shorter RFS in KRAS Mute and
BRAF Mute patients with stage
III tumors (P < .05)
600 All Mute: 13.8 months (95% CI,
9.2-18.4) vs BRAF/PIK3CA Mut:
6.3 months (95% CI, 1.3-11.3;
P < .05)
All Mute: 6.1 months (95% CI,
3.1-9.2) vs BRAF/PIK3CA Mutþ:
1.6 months (95% CI, 1.5-1.7;
P < .05)
All Mute: 38.8% vs BRAF/PIK3CA
Mutþ: 0%, P < .05
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Table 9 Summary of Frequencies of Tumor V600E Mutation Status*
Sample Group
No. of
Studies
Positive
p.V600E, No.
Negative BRAF
p.V600E, No. BRAF p.V600E, % (95% CI)
Known negative MMR mutation status
MSI-H known mutation status 11 115 216 36.10 (20.95-52.84)
MLH1 methylation or MLH1 loss of expression
(known or assumes MSI-H status)
9 191 141 63.50 (46.98-78.53)
MSS 11 85 1,538 5.00 (3.55-6.68)
Known positive MMR mutation status
All mutation carriers 26 4 546 1.40 (0.06-2.25)
BRAF, proto-oncogene B-Raf/v-Raf murine sarcoma viral oncogene homolog B; CI, confidence interval; MMR, mismatch repair; MSI-H, microsatellite
instability high; MLH1, mutL homolog 1; MSS, microsatellite stable.
*Adapted from Parsons et al52 by permission from BMJ Publishing Group Limited.
Sepulveda et ala mutation in BRAF and dMMR, it may be concluded that
the basis for their dMMR is less likely to be germline.5,52,62
In contrast, tumors with dMMR in the absence of a BRAF
mutation may have either germline or an epigenetic (MLH1
gene promoter hypermethylation) basis for the dMMR, and
specific testing for MLH1 promoter hypermethylation may
be used to further refine the risk of Lynch syndrome before
initiating definitive genetic testing. Identification of those
patients with germline-based dMMR has clear implications
for the patient’s family members.
3. Recommendation: Clinicians should order mismatch
repair status testing in patients with colorectal cancers for
the identification of patients at high risk for Lynch syn-
drome and/or prognostic stratification.
The molecular pathology underlying most MSI tumors is
somatically acquired CpG methylation of the promoter of
the gene, MLH1. About three-fourths of colorectal cancers
with MSI due to MLH1 promoter hypermethylation will
have an acquired BRAF mutation as well. The reason for this
is not understood. Less than one-third of individuals withTable 10 Mismatch Repair/Microsatellite Instability Systematic Review
Author, Year Study Type and Evidence Comparison Tests Used
Guastadisegni
et al,7 2010
SR: 31 studies including
12,782 patients with
CRC
MSI vs MSS MSI by PCR i
IHC in 6 st
Des Guetz
et al,6 2009
SR: 7 studies including
3,690 patients with CRC
on effect of adjuvant
chemotherapy
1,444 treated with 5-FU
ebased therapy and
1,518 not treated
MSI vs MSS PCR in all an
2 studies
CI, confidence interval; CRC, colorectal cancer; DFS, disease-free survival; 5
microsatellite instability; MSI-H, microsatellite instability high; MSS, microsate
polymerase chain reaction; PFS, progression-free survival; RFS, relapse-free surviv
204dMMR/MSI colorectal tumors do not have underlying
MLH1 promoter hypermethylation but rather have a germ-
line mutation affecting any one of the four DNA MMR
genes noted above. Individuals with germline mutations in
the MMR genes are said to have Lynch syndrome, an
autosomal dominant disorder that confers dramatically
increased risks for colorectal and endometrial cancers and
moderately increases risks for a variety of other tumors.63
Diagnosis of Lynch syndrome is important as active man-
agement of cancer risks has been demonstrated to benefit
gene mutation carriers,5,64,65 and establishing a diagnosis
creates opportunities for prevention among all at-risk rela-
tives. Testing for dMMR can be performed by immuno-
histochemistry for the four MMR proteins (MLH1, MSH2,
PMS2, and MSH6) or by MSI DNA-based testing, as dis-
cussed in detail in a report by Funkhouser et al66 (recom-
mendation 11).
A systematic review of 31 studies7 reporting survival on
12,782 patients whose tumors were characterized for MSI
showed a favorable prognosis, as determined by both OSs
OS PFS
n all and
udies
OR, 0.6; 95% CI, 0.53-
0.69, P < .0001, MSI is
associated with longer
survival
DFS, OR, 0.58; 95% CI,
0.47-0.72, P < .0001,
MSI is associated with a
longer PFS duration
d IHC in MSI-H:
HR, 0.70; 95% CI, 0.44-
1.09, P Z ns; no
significant benefit of
chemotherapy in MSI-H
patients
MSI-H:
RFS, HR, 0.96; 95% CI,
0.62-1.49, P Z ns; no
significant difference if
treated or not treated
MSI-H vs MSS:
RFS, HR, 0.77; 95% CI,
0.67-0.87, P < .05, MSI
patients had no effect
of treatment compared
with beneficial effect in
MSS patients
-FU, 5-fluorouracil; HR, hazard ratio; IHC, immunohistochemistry; MSI,
llite stable; ns, nonsignificant; OR, odds ratio; OS, overall survival; PCR,
al; SR, systematic review.
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ASCP/CAP/AMP/ASCO CRC Biomarker Guidelineand DFS (Table 10), but this is dependent on stage. In
addition, the presence of MSI in CRC was reported to be
predictive for nonresponse to 5-fluorouracilebased adjuvant
chemotherapy of early stage disease,6 although this has not
been corroborated (Table 10).67 Emerging data indicate that
MMR status may have predictive value in some settings,
specifically in patients with advanced disease being
considered for anti-programmed cell death protein-1 (PD-1)/
programmed cell death ligand protein-1 (PD-L1) immune
checkpoint inhibitor therapy.68-70
This recommendation is supported by two systematic
reviews that included 38 studies and 16,472 patients.6,7
Both of these systematic reviews included a well-
described and reproducible methods section, and both re-
ported on potential conflicts of interest. Only one, the sys-
tematic review reported by Guastadisegni et al,7 reported the
source of funding, which was nonindustry. Due to deficits in
the reporting, one of these systematic reviews was deemed
to have a moderate risk of bias,6 and the other was deemed
to have a low to moderate risk of bias7; however, neither of
these were found to have any major methodologic flaws that
would cause us to question their findings.
4. No Recommendation: There is insufficient evidence
to recommend BRAF c.1799 (p.V600) mutational status as a
predictive molecular biomarker for response to anti-EGFR
inhibitors.
As noted in recommendation 2a, mutations in position
p.V600 in BRAF are associated with poor prognosis,
especially in patients with metastatic disease. Response
rates to chemotherapy regimens, including regimens with
cetuximab and panitumumab, are lower in patients
harboring BRAF p.V600 mutations51,53,71 (Table 8).
Similarly, the PFS and OS after treatment with EGFR
monoclonal antibodies in combination with chemotherapy
are lower in patients with BRAF p.V600 mutations.47,48
Many of these analyses used nonrandomized cohorts,
thereby making evaluation of the potential predictive value
of the BRAF p.V600 mutation impossible to discern
(Table 8). In addition, the poor prognosis and low muta-
tion prevalence make evaluation of the relative benefit of
EGFR inhibitors difficult to evaluate in individual ran-
domized clinical trials.
Meta-analyses of randomized studies of EGFR mono-
clonal antibodies have been completed to address the
question of the predictive role of BRAF p.V600 mutations.
A meta-analysis of 463 patients with KRAS wild-type and
BRAF p.V600 mutated tumors did not provide sufficient
evidence to exclude a magnitude of benefits seen in KRAS/
BRAF wild-type tumors. Nor was there sufficient evidence
to identify a statistically significant benefit to this treat-
ment.55 A second meta-analysis showed that EGFR mono-
clonal antibody treatment in patients whose tumors contain
a BRAF p.V600 mutation was not associated with signifi-
cant OS (P Z .43), although there was a trend for better
PFS (P Z .07).72 This suggests insufficient evidence toThe Journal of Molecular Diagnostics - jmd.amjpathol.orgrecommend the use of BRAF p.V600 as a predictive marker
for benefit of anti-EGFR monoclonal antibodies. More data
are required to definitively determine the predictive value of
BRAF mutations relative to anti-EGFR therapy.
This recommendation was supported by five systematic
reviews47,48,51,53,71 (Table 8). None of these systematic re-
views reported forming a multidisciplinary panel, and none
reported including patient representatives in developing their
research questions or interpreting their outcomes. All of the
systematic reviews examined important patient subtypes, and
all used well-described and reproducible methods. Only the
systematic review by Yuan et al48 reported on any potential
conflicts of interest, the article by Mao et al51 stated conflicts
were not examined, and the other three did not report any-
thing regarding conflicts.47,53,71 Only two, the systematic
reviews reported by Yang et al71 and Yuan et al,48 rated the
quality of the included evidence, although none of the studies
reported on the strength of the evidence. None of the studies
discussed any plans for future updating. Four reported
nonindustry funding for their systematic reviews,48,51,53,71
and one did not report the source of funding, if any.47 Two
of the systematic reviews were deemed to have a low risk
of bias,48,71 one was deemed to have a low to moderate risk of
bias,47 and two were deemed to have a moderate risk of
bias.51,53 Overall, none of the systematic reviews were found
to have methodologic flaws that would raise concerns about
their findings.
5. No Recommendation: There is insufficient evidence
to recommend PIK3CA mutational analysis of colorectal
carcinoma tissue for therapy selection outside of a clinical
trial.
Note: Retrospective studies have suggested improved
survival with postoperative aspirin use in patients whose
colorectal carcinoma harbors a PIK3CA mutation.
Despite comprehensive RAS testing (recommendation 1),
many patients still fail to respond to EGFR monoclonal
antibody therapy. Additional biomarkers to guide patient
selection for such therapy are desired.
PIK3CA mutations are observed in 10% to 18% of pa-
tients with CRC, primarily in exons 9 and 20, and lead to a
constitutive activation of p100a enzymatic activity, leading
to an increased PI3K activity and high oncogenic trans-
formation ability. However, mutations of KRAS or NRAS
and PIK3CA mutations can be detected alternatively and, in
some cases, concurrently in a single CRC.3,8 PIK3CA mu-
tations are positively correlated with KRAS exon 12 and 13
mutations.3 Several meta-analyses and one individual pa-
tient data large pooled analysis have examined the prog-
nostic role of PIK3CA in patients with stage IV CRC, both
overall and in the KRAS nonmutated/wild-type population.
These studies have generally indicated poorer response rate
and PFS in patients with the PIK3CA mutation, a finding
that appears to be driven primarily by patients with exon 20
mutation3,33,50,71 (Table 11). These meta-analyses have
included many of the same studies, as well as observed and205
Table 11 PIK3CA Clinical Practice Guidelines, Systematic Reviews, Meta-Analyses, Prospective Cohort Studies, and Retrospective Cohort
Studies
Author, Year Study Type and Evidence Comparison Tests Used
CPGs, systematic reviews, and meta-analyses on PIK3CA Mutþ vs Mute (n Z 5)
Wu et al,73 2013 SR: 8
839 patients with mCRC who all received
anti-EGFR mAbs
Mutþ vs Mute Sanger, allelic discrimination, direct
sequencing, pyrosequencing
Mao et al,33 2012 SR: 13 studies including patients all KRAS
Mutetreated with anti-EGFR mAbs
E20 Mutþ vs E20 Mute NR
Lin et al,50 2011 SR: 4 studies 1,030 patients with mCRC,
all KRAS Mute subgroup analysis,
exons 9 and 20
Mutþ vs Mute NR
Baas et al,20 2011 SR: 3 studies including 195 patients with
mCRC
Mutþ vs Mute Sequencing, pyrosequencing
Yang et al,71 2013 SR: 10 studies (patient number Z NR) Mutþ vs Mute DS, PCR amplification, AS-PCR,
genotyping, RT-PCR, Sanger, DNA
sequencing, pyrosequencing
Retrospective cohort studies (n Z 1)
Bando et al,43 2013 82 samples from 376 patients All Mutevs BRAF Mutþ
and PIK3CA Mutþ
Luminex xMAP vs DS (concordance
rate 100%)
(table continues)
AS-PCR, allele-specific polymerase chain reaction; CI, confidence interval; CPG, clinical practice guideline; DS, direct sequencing; EGFR, epidermal growth
factor receptor; HR, hazard ratio; mAbs, monoclonal antibodies; mCRC, metastatic colorectal cancer; Mute, mutation negative or wild type; Mutþ, mutation
positive; NR, not reported; ns, nonsignificant; ORR, objective response rate; OS, overall survival; PCR, polymerase chain reaction; PFS, progression-free
survival; PIK3CA, phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha; RD, risk difference; RR, response rate; RT-PCR, reverse transcription
polymerase chain reaction; SR, systematic review; xMAP, multiplex assay.
Sepulveda et alacknowledged between-study heterogeneity, and all have
concluded further prospective data are necessary. Contra-
dictory recent studies have also been recently reported.74
None of the studies considered the independent role of
PIK3CA in the context of comprehensive RAS testing. De
Roock et al3 estimated that comprehensive PIK3CA testing
would increase response rate in the first-line setting by only
1%. The prognostic impact of PIK3CA in stage I to III
disease has been inconsistent.75-77
Multiple prospective observational studies have demon-
strated an association between aspirin use and decreased
CRC mortality.78-80 Data on aspirin as a treatment for CRC
(postdiagnosis usage) are more limited and drawn only from
observational studies. Domingo et al81 and Liao et al82
found a survival advantage for posttreatment aspirin users
only in patients whose tumors exhibit PIK3CA mutations;
however, a recent cohort study did not validate these ob-
servations.83 Multiple prospective studies are under way to
address the potential benefit of adding aspirin or other
nonsteroidal anti-inflammatory drugs to adjuvant therapy.
This recommendation is supported by two systematic
reviews33,40 obtained from our systematic review. None
reported the composition of a multidisciplinary panel, re-
ported patient representation or study quality, rated strength
of the evidence reviewed, or disclosed a plan for updating.206However, both systematic reviews did include relevant pa-
tient subgroups and included methods that were well
described and reproducible. In both systematic reviews,
information about the potential conflicts of the panelists was
reported, and funding was provided by nonindustry sources.
Both were found to have a moderate risk of bias, but neither
of the studies providing the evidence base for recommen-
dation 5 were found to have methodologic flaws that would
raise concerns about their findings.
At the present time, the retrospective data for the use of
PIK3CA mutation to deny anti-EGFR antibody therapy in
patients with stage IV CRC or as a selection factor for use of
aspirin in stage I to III tumors are insufficient for clinical use
outside of a clinical trial.
6. No Recommendation: There is insufficient evidence
to recommend PTEN analysis [expression by immunohis-
tochemistry (IHC) or deletion by fluorescence in situ hy-
bridization (FISH)] in colorectal carcinoma tissue for
patients who are being considered for therapy selection
outside of a clinical trial.
PTEN functions as a tumor suppressor gene, and loss of
PTEN results in upregulation of the PI3K/AKT pathway.
PTEN mutations occur in approximately 5% to 14% of
colorectal cancers,4,84 and loss of PTEN expression can bejmd.amjpathol.org - The Journal of Molecular Diagnostics
Table 11 (continued)
Codons Studied OS PFS ORR
Exons 9, 20 HR, 1.28; 95% CI, 1.05-1.56, P < .05,
patients with PIK3CA Mutþ had
shorter PFS
PFS, HR, 1.53; 95% CI, 1.28-1.84,
P < .05, patients with PIK3CA Mutþ
had shorter PFS
NR
Exon 20 HR, 3.29; 95% CI, 1.60-6.74; P < .05 PFS, HR, 2.52; 95% CI, 1.33-4.78,
P < .05, PIK3CA exon 20 mutations
associated with shorter PFS
ORR%:
Exon 20 Mutþ: 0;
Exon 20 Mute: 37%
RR, 0.25; 95% CI, 0.05-1.19, P Z ns
(subset: 377 patients)
Exons 9, 20 P Z ns, no difference between Mutþ
and Mute patients
Exon 20 Mutþ predicts poorer survival
P Z ns, no difference between Mutþ
and Mut- patients
Exon 20 Mutþ predicts poorer survival
NR
Exons 9, 20 NR NR NR
Exons 7, 8, 9,
18, 19, 20
(6 studies)
HR, 1.43 (95% CI, 1.02-2.0; P < .05)
in favor of Mute
(6 studies)
HR, 1.91 (95% CI, 0.78-4.68; PZ ns)
P < .05 in favor of exon 9 compared
with exon 20 mutations
(6 studies)
RD: e23% (-35%, -10%; P < .05) in
favor of exon 9 compared exon 20
mutations
Exon 9 All Mute: 13.8 months (95% CI, 9.2-
18.4) vs BRAF/PIK3CA Mutþ: 6.3
months (95% CI, 1.3-11.3; P < .05)
All Mute: 6.1 months (95% CI, 3.1-
9.2) vs BRAF/PIK3CA Mutþ: 1.6
months (95% CI, 1.5-1.7; P < .05)
All Mut-: 38.8% vs BRAF/PIK3CA
Mutþ: 0, P < .05
ASCP/CAP/AMP/ASCO CRC Biomarker Guidelineobserved in tumors with KRAS, BRAF, and PIK3CA
mutations.
Although there is evidence suggesting that PTEN is a
critical factor in cancer development, the association be-
tween PTEN expression and predictive/prognostic value
remains controversial, with several studies suggesting an
association with poorer prognosis and others finding no
association at all. Four systematic reviews were obtained
that reported on loss of PTEN expression compared with
normal PTEN expression and 31 primary studies, including
a total of 2,545 patients20,50,85,86 (Supplemental Table 14).
Tests used included IHC and FISH. Of the four studies that
reported overall survival rates,20,50,85,86 three studies re-
ported on pooled outcomes.50,85,86 One study reported a
significant difference in favor of normal PTEN expression,86
and the others reported no significant differences.20,50,85 For
PFS, three studies pooled outcomes,50,85,86 two detected a
significant difference in favor of normal PTEN expres-
sion,85,86 and one showed no significant difference.50 For
ORR, two studies pooled outcomes, and both found loss of
PTEN expression associated with a poorer response.85,86
Several studies have shown an association between PTEN
loss and local recurrence, advanced TNM stage, lymph node
metastasis, and a lower 5-year survival rate.87-90 However,
several other studies have found no correlation between
PTEN status and patient survival, tumor grade, TNM stage,
lymphatic invasion, and liver metastasis.91-93 Regarding
response to EGFR-targeted therapies, several studies haveThe Journal of Molecular Diagnostics - jmd.amjpathol.orgshown an association with PTEN loss and lack of response
to cetuximab and panitumumab.94-97 However, other pub-
lished studies failed to demonstrate a clear correlation
between loss of PTEN expression and response to anti-
EGFR therapy.98-100 Given the significant discordance in
results, the role of PTEN as a prognostic or predictive
biomarker in CRC is still largely unknown, and research
into the prognostic and predictive significance of PTEN is
ongoing.
This recommendation is supported by 20 studies,4,20,50,
84-100 four20,50,85,86 of which met the inclusion criteria for
inclusion in our systematic review. All four of these were
systematic reviews and included 42 studies and 3,412 pa-
tients. None of these systematic reviews reported using a
multidisciplinary panel or reported including the patient
perspective or a plan for future updating. Three50,85,86 re-
ported on important patient subgroups. All four had well-
described and reproducible methods sections. Three20,50,86
reported that potential conflicts of interest were examined.
Only two50,86 rated the quality of the included evidence, and
these same two were also the only two that rated the strength
of the evidence. Only three20,50,86 reported on the source of
any funding, but all three reported nonindustry funding. One
was deemed to have a low risk of bias,50 one was deemed to
have a low to moderate risk of bias,86 and two were deemed
to have a moderate risk of bias.20,85 None of the studies
were found to have any methodologic flaws that would
bring doubt to their findings.207
Sepulveda et al7. Expert Consensus Opinion: Metastatic or recurrent
colorectal carcinoma tissues are the preferred specimens for
treatment predictive biomarker testing and should be used if
such specimens are available and adequate. In their absence,
primary tumor tissue is an acceptable alternative and should
be used.
In clinical practice, one or more specimens of CRC from an
individual patient may become available for molecular testing
during the course of the disease. These specimens may include
initial diagnostic biopsy or surgical resection specimens of the
primary tumor and resection, biopsy, or cytologic specimens
from metastatic and recurrent tumor. Discordance between
primary andmetastatic lesionsmay be attributed to a number of
mechanisms, including tumor heterogeneity already present in
the primary tumor, tumor evolution,where novelmutations are
acquired, and, in some cases, the presence of separate pri-
maries. The systematic literature review for the CRC guideline
was done to identify studies that compared the mutational
status of primary vs metastatic CRC.
An earlier systematic literature search that was conducted
to include studies testing concordance of KRAS, BRAF,
PIK3CA, and loss of PTEN expression in CRC20 reported
the results of 21 studies, with an overall concordance rate of
93% (range, 76%-100%) for KRAS, 93% for BRAF status, a
range of 89% to 94% for PIK3CA, and 68% for loss of
PTEN. Table 12 shows the summary of two subsequent
studies where KRAS, NRAS, BRAF, and PIK3CA mutation
and PTEN expression were compared in paired primary vs
metastatic tumor lesions.101,102 Overall concordance rates
between primary and metastatic lesions were high withmore
than 90% concordance (Table 12).101,102 In the study by Lee
et al, analysis of KRAS mutation in primary and recurrent
tumors after radical resection showed 20.3% discordance.103
This recommendation was supported by two retrospective
cohort studies101,102 that were obtained in the systematic
review. Both of these studies compared results within aTable 12 Concordance Rates Between Primary and Metastatic
Lesions*
Genes Tested (n) Concordance Rate, %
KRAS (117)101 91.0
KRAS, NRAS, BRAF (84)102 98.8
PIK3CA (117)101 94.0
PIK3CA (84)102 92.8
PTEN IHC (117)101 66.0
*Summary of two randomized clinical trials where comparison of muta-
tion in KRAS, NRAS, BRAF, and PIK3CA was performed for paired primary
tumor and metastatic lesions. Immunohistochemistry for PTEN was done in
Cejas et al.101 In the study by Cejas et al,101 metastases were synchronous
or metachronous. DNA was extracted from formalin-fixed, paraffin-
embedded tissue, and mutational analysis was performed with a polymerase
chain reactionedirect sequencing assay. KRAS mutations were detected in
42% of metastatic lesions and 39% of primary tumors. In the study by
Vakiani et al,102 DNA was extracted from frozen tissue, and the iPLEX
(Agena Bioscience, San Diego, CA) assay was used to examine the following
mutations: KRAS 12, 13, 22, 61, 117, and 146; NRAS 12, 13, and 61; BRAF
600; and PIK3CA 345, 420, 542, 545, 546, 1043, and 1047.
208single cohort. The study reported by Cejas et al101 reported
at least partial industry funding, and the study reported by
Vakiani et al102 did not report the source of funding, if any.
The study by Cejas et al101 was deemed to have a low to
moderate risk of bias, and the study by Vakiani et al102 was
deemed to be low. Overall, neither of these studies had any
methodologic flaws that would raise concerns about the
reported findings.
In summary, given that discordance of mutational status
between primary and metastatic or recurrent CRC lesions
may occur in a number of cases, metastatic or recurrent
CRC tissues are the preferred specimens for treatment pre-
dictive biomarker testing. However, if these specimens are
not available, primary tumor tissue is an acceptable alter-
native, given the overall high rates of concordance for the
mutation status of EGFR pathway genes.
8. Expert Consensus Opinion: Formalin-fixed, paraffin-
embedded (FFPE) tissue is an acceptable specimen for
molecular biomarker mutational testing in colorectal carci-
noma. Use of other specimens (eg, cytology specimens) will
require additional adequate validation, as would any
changes in tissue-processing protocols.
The systematic review identified a number of studies,
summarized in Table 13, where CRC KRAS mutational
testing was performed using FFPE specimens as well as
fresh or frozen specimens. Recommendation 17 highlights
the importance of review of stained sections of tumor
selected for testing by a pathologist to verify the tumor cell
content population of the sample and demarcate regions for
potential macrodissection or microdissection to enrich for
cancer cells. Biopsy and resection specimens are similarly
acceptable, as long as sufficient tumor cells are present
(Table 13). Cytology specimens may be adequate for testing
but will require proper validation. The use of FFPE cell
blocks allows for the evaluation of tumor cell content and
viability.104 Laboratories will need to establish the mini-
mum tumor cell content for specimens based on the per-
formance characteristics of their validated assay.105,126
Liquid biopsy tests use serum or plasma and may be used
for monitoring tumor recurrence and emergence of treat-
ment resistance. The noninvasive nature of this approach
(monitoring through blood testing) offers great potential for
clinical use.106 However, at the present time, the clinical
application of liquid biopsy assays awaits robust validation
and further studies to determine their clinical utility.
9. Strong Recommendation: Laboratories must use
validated colorectal carcinoma molecular biomarker testing
methods with sufficient performance characteristics for the
intended clinical use. Colorectal carcinoma molecular
biomarker testing validation should follow accepted stan-
dards for clinical molecular diagnostics tests.
Clinical validation assesses the molecular biomarker
testing method in light of clinical characteristics of the
disease or marker being tested, to ensure the test is “fit for
purpose.” Elements of clinical validation include analyticaljmd.amjpathol.org - The Journal of Molecular Diagnostics
ASCP/CAP/AMP/ASCO CRC Biomarker Guidelinesensitivity, analytical specificity, clinical sensitivity, and
clinical specificity. Data for clinical validation can be ob-
tained from studies performed by the laboratory, studies
reported in peer-reviewed literature, or other reliable sour-
ces. CLIA requires clinical laboratories to have a qualified
laboratory director who is responsible for ensuring that the
laboratory provides quality laboratory services for all as-
pects of test performance.107 Rigorous validation should be
performed to ensure all molecular marker testing methods,
such as those used for colorectal carcinoma, are ready for
implementation in the clinical laboratory. To reach that goal,
each step of the testing process must be carefully evaluated
and documented. Excellent and comprehensive documents
have been published on this topic, and a detailed review is
provided under recommendation 10. Our systematic review
of the available literature provided information regarding
the performance characteristics of molecular marker testing
methods of colorectal carcinoma in clinical use for RAS
mutational testing (Table 13). Most studies reported the
performing characteristic of assays that detected KRAS exon
2 mutations, as detailed in Table 13. Direct sequencing of
genomic DNA, even after polymerase chain reaction (PCR)
amplification of the fragment of interest, has low analytical
sensitivity requiring a mutant allele frequency of about 20%
for mutation detection. A number of more sensitive assays
have been developed for RAS testing, including those listed
in Table 13.
Sanger sequencing was used as the most common
baseline assay for comparison against other molecular
detection methods for KRAS mutations. Testing methods
vary widely, including direct Sanger sequencing, amplifi-
cation refractory mutation system, real-time PCRehigh-
resolution melting (HRM) assays, allele-specific PCR,
Luminex (Austin, TX) bead microarray, PCR restriction
fragment length polymorphism strip assays, pyrosequenc-
ing, and, more recently, NGS. Population or clinical
sensitivity of the testing methods for KRAS mutations as
shown in Table 13 ranged between 36% and 59%. Assay
sensitivity ranged from 84.4% to 100%, with Sanger
sequencing on the lower end of the range. Analytical
sensitivity, defined as the lowest detectable mutant allele
fraction, was between 0.5% and 20% across all testing
methods, with most methods performing between 1% and
5% mutant allele fraction. Specificity was between 98%
and 100% for most assays, with two studies demonstrating
lower specificity. Positive predictive value percentages
varied between 66% and 100%, with most studies reporting
between 99% and 100%. Negative predictive value per-
centages were between 97% and 100%. Minimal tumor
percentages reported varied widely between studies.
Concordance between assays was between 93% and 100%,
with some variability noted in two retrospective cohort
studies. The available evidence from assays to detect KRAS
mutations supports the use of a number of alternative
assays, as long as their performing characteristics, adjusted
for sample type and percent tumor purity, meet the clinicalThe Journal of Molecular Diagnostics - jmd.amjpathol.orgsensitivity with acceptable specificity. Recently, NGS has
been used in a number of studies and in laboratory practice
for solid tumor mutational analysis.108 NGS has shown to
meet the sensitivity of detection used in CRC clinical trials
(detecting at least 5% mutant alleles), permitting simulta-
neous testing of hundreds of mutations, and is becoming
widely used. Testing for mutations in multiple genes or
gene loci with multiplex assays such as NGS and other
methods should be done on patients at the time of me-
tastases to obtain comprehensive genomic information and
identify mutations beyond RAS/BRAF status that might be
able to be targeted if conventional therapies become
ineffective.
10. Strong Recommendation: Performance of molecular
biomarker testing for colorectal carcinoma must be vali-
dated in accordance with best laboratory practices.
Proper validation of CRC biomarker testing is important
to ensure appropriate patient care. If validation is inade-
quate, this can lead to erroneous results and improper
diagnosis, prognosis, and/or therapeutic intervention. For
example, with regard to RAS testing, a false-positive result
would lead to an improper withholding of therapy, whereas
a false-negative result would lead to distribution of an
ineffective therapy, resulting in increased costs and unnec-
essary side effects. As molecular oncology testing grows
more complex with NGS, thorough and proper validation of
preanalytical (specimen type and processing), analytical
(assay performance), and postanalytical (bioinformatics,
annotation, and reporting) steps is imperative.109,110
The design of a validation study somewhat depends on
the analyte (gene), mutations, or molecular alterations
assessed and chosen platform and technology. However,
assay validation should be done using best laboratory
practices in accordance with CLIA (42 CFR
493.1253(b)(2), also known as Title 42 Chapter IV Sub-
chapter G Part 493 Subpart Kx493.1253)111 as applicable to
the assay type. Laboratories should comply with CLIA and
their individual accrediting agency (eg, CAP, New York
State) to fulfill requirements for validation.111,112 Additional
resources for establishing clinical molecular testing are
available to assist laboratories.113 For the US Food and
Drug Administration (FDA)ecleared/approved assays
(without any modification), verification of test specifica-
tions, including accuracy, precision, reportable range, and
reference range, only needs to be done.114 For nonwaived,
noneFDA-approved assays (laboratory-developed proced-
ures or LDPs), validation must be performed. Validation
design must include the required elements of analytical
accuracy (specificity and sensitivity), precision, and
analytical sensitivity (limit of detection) and interfering
substances and reportable range as applicable. Clinical
sensitivity and specificity, as well as positive and negative
predictive value, should be considered additions.
Additional considerations should include specimen
processing (including microdissection or macrodissection,209
Table 13 Comparison of Test Performing Characteristic of Assays for KRAS Mutation Detection
Author, Year No. Comparison Testing Method Codons Tissue Site Procedure
Sample
Type
Ma et al, 2009130 100 Sequencing HRM 12, 13 Primary NR FFPE
Pinto et al, 2011131 372 Consensusz Sequencing 12, 13 NR NR FFPE
184 DxS
182 HRM
372 Snapshot
Tol et al, 2010132 511 Sequencing DxS 12, 13 Primary Resection Frozen
Buxhofer-Ausch et al, 2013133 60 Sequencing SA 12, 13 Primary NR Biopsy
Chang et al, 2010136 60 Sequencing MPCR PE 12, 13, 61 Primary NR Frozen
Chen et al, 2009137 90 Sequencing SSCP 12, 13 Primary NR Fresh
Chow et al, 2012138 204 Sequencing ASP 12, 13 NR NR FFPE
Sundstrom et al, 2010142 100 DxS Pyro 12, 13, 61 Primary or met Biopsy
Franklin et al, 2010128 59 Sequencing HRM 12, 13 Primary Resection FFPE
59 Sequencing ARMS 12, 13 NR
Laosinchai-Wolf et al, 2011129 86 Sequencing BMA 12, 13 Primary NR FFPE
Carotenuto et al, 2010134 540 Sequencing DxS 12, 13 Primary NR FFPE
540 Sequencing Sanger
Cavallini et al, 2010135 112 DxS SA 12, 13 NR NR FFPE
112 DxS PCR-RFLP
Kristensen et al, 2010139 61 COLD-PCR DxS 12, 13 Primary Resection FFPE
61 PCR MCA
Kristensen et al, 2012140 100 CADMA DxS 12, 13 Primary Resection FFPE
100 DxS CADMA
Lang et al, 2011141 125 Sequencing ASP 12, 13 Primary Resection FFPE
(table continues)
ARMS, amplification refractory mutation system; ASP, allele specific (nonquantitative); BMA, Luminex bead microarray; CADMA, competitive ampli-
fication of differentially melting amplicons; COLD-PCR, coamplification at lower denaturation temperature-PCR; DxS, QIAGEN method; FFPE, formalin
fixed, paraffin embedded; HRM, high-resolution melting; M, missing; MCA, melting curve analysis; met, metastatic; MPCR PE, multiplex polymerase chain
reaction (KRAS, NRAS, HRAS ) and primer extension; NPV, negative predictive value; NR, not reported; PPV, positive predictive value; PCR-RFLP,
polymerase chain reactionerestriction fragment length polymorphism; PCS, prospective cohort study; Pyro, pyrosequencing; RCS, retrospective cohort study;
SA, KRAS-BRAF strip assay; SSCP, single-strand conformation polymorphism.
*Population or clinical sensitivity of testing method (%) of cases positive for KRAS mutation tested.
yFour (9.5%) of 42 samples negative for KRAS mutation by direct sequencing were positive for KRAS mutations by HRM analysis.
zTotal of 84.4% of consensus mutation result.
xDetected one mutation in 23 Mut- alleles.
{Variable concordance for different tumor percentage in the sample.
kThe sensitivity was increased by 5- to 100-fold for melting temperature decreasing mutations when using coamplification at lower
denaturation temperature-PCR (COLD-PCR) compared with standard PCR. Mutations, undetectable by the TheraScreen (QIAGEN, Valencia, CA)
kit in clinical samples, were detected by coamplification at lower denaturation temperature-PCR followed by HRM and verified by sequencing.
Sequencing (PCR of fragment of interest followed by sequence analysis) described as direct sequencing.
Sepulveda et alhistologic processing, and fixation times) and reagent
stability and storage. Proper controls should be introduced
and used to assess as many of the potential mutations
detected by the assay and to verify the limit of detection
identified in the validation. With high-throughput (NGS)
sequencing, assessing all possible mutations through
control material and specimens is impossible, and
continuing validation may need to occur. If NGS is used,
bioinformatics pipelines should be properly validated
using multiple types of mutations (single-nucleotide
variants and insertions/deletions). Finally, reporting
should be carefully considered during the validation210process. Resources to assist laboratories with solid tumor
molecular testing have also been made available through
the CLSI.115
Preanalytical Variables
Histologic or preanalytical processing should be considered
and representative processes should be included in the
validation set. Specific specimen types should also be
properly validated. Most tissue used in CRC biomarker
testing is derived from FFPE tissue. Formalin fixation re-
sults in fragmentation of DNA as a result of histone protein
fixation to the DNA. Therefore, most assays for FFPE tissuejmd.amjpathol.org - The Journal of Molecular Diagnostics
Table 13 (continued)
Population
Sensitivity
of Testing
Method, %*
Sensitivity
of Assay
Analytical
Sensitivity, %
(Mutant Allele
Fraction) Specificity, % PPV, % NPV, %
Minimal
Tumor, %
Concordance
Between
Assays, % Study
59 Increasedy (>100) 5-10 98 NR NR 30 95 PCS
36.4 84.4z 15-20 NR NR NR >50 NR PCS
43.1 96 1 NR NR NR NR
42.7 98 3-10 NR NR NR NR
43.3 99 5 NR NR NR NR
39.4 96.5 1 99.7 99.5 97.2 3-90 95.30 PCS
47.0 100 1 100 NR NR At least 50 100 PCS
34.0 100 NRx 100 100 100 NR 100 PCS
36.0 100 NR 100 100 100 NR 100 PCS
40.7 100 1.25-2.5 100 100 100 NR NR PCS
39.0 91 1.25-2.5; 1.25 NR NR NR NR NR PCS
54.0 100 1 87 81 100 1-90 NR RCS
43 100 5 71 66 100 1-90 93 RCS
45.0 100 1 100 100 100 NR NR or M RCS
38.6 95.8 1 100 100 97.3 <30 vs >70 Variable{ RCS
98.6 NR 100 100 99.1 NR NR RCS
92.5-100 NR 100 NR NR 70 NR RCS
92.5-100 NR 100 NR NR NR NR RCS
NR 93 0.1-5 100 NR NR NR k RCS
97 5-10 100 NR NR NR RCS
44.4 98 0.50 98 NR NR NR 95.9 RCS
99 NR 100 NR NR NR NR RCS
36.8 95.7x 1 NR NR NR >50 NR RCS
ASCP/CAP/AMP/ASCO CRC Biomarker Guidelineare designed to amplify products less than 200 base pairs.
Length of formalin fixation and age of blocks may also be
factors to consider in validation of FFPE tissues. Other
tissue sources should also be separately validated if offered
as clinical tests, especially cytology-based specimens.
Various cytology fixative preparations should be validated
as used by the laboratory. If cell-free assays are considered,
these should be validated as a separate source. Finally,
testing should be limited to invasive carcinoma with
exclusion of adenomatous tissue and benign background
tissue cellular components (eg, normal mucosa, muscularis,
inflammation) as much as possible.
Analytical Variables
Careful specimen selection should be undertaken to cover as
many of the potential detected mutations and expected
specimen types as possible to ensure analytical accuracy. A
gold-standard method (dideoxy sequencing or other vali-
dated test method) and/or interlaboratory comparison should
be used to verify accuracy of the assay. For example, the
CAP Laboratory Accreditation Program COM.40350 in-
dicates that at least 20 specimens (including positive, low-
positive, and negative specimens) should be included for
qualitative and quantitative assays.112 More specimens mayThe Journal of Molecular Diagnostics - jmd.amjpathol.orgbe required. If it is a single-gene assay, the design should
include as many of the mutations covered by the assay as
possible. If it is a real-timeebased allele-specific assay, all
mutations for which a primer probe reaction is built should
be analyzed as reasonably as possible. If it is a
pyrosequencing-based assay, similarly, all of the possible
common mutations for which targeted therapies are indi-
cated should be tested. Multigene assays based on NGS or
other technology [such as SNaPshot (ThermoFisher Scien-
tific, Waltham, MA)] require an increased number of
specimens to test as many of the hotspot regions as possible
in all genes included in the assay. With such assays, not all
possible mutations can be validated. It is recommended that
an ongoing validation occur after initial validation, with
verification of novel mutations by either dideoxy
sequencing or real-time PCR, depending on the laboratory
capability and limit of detection. Depending on the tech-
nology employed, important parameters (eg, variant allele
frequency, cyclic threshold values, allele coverage) should
be monitored for interrun and intrarun precision.
CRC specimens can vary from large primary resection
blocks with plenty of tumor cells to small primary tumor or
metastatic CRC liver biopsy specimens to rectal specimens,
after neoadjuvant therapy with minimal tumor percentage.211
Sepulveda et alMany of these tests are ordered for metastatic disease, for
which only a small needle core biopsy specimen or cyto-
logic sampling is available. Presently, tissue volume and
accessibility are decreasing while ancillary testing (IHC
and molecular studies) is increasing. The ability of an assay
to be highly analytically sensitive is important if a labo-
ratory is to test specimens with low tumor burden. It is
recommended that an assay be able to identify a mutation in
a specimen that has at minimum 20% tumor cells (mutant
allele frequency of 10% assuming heterozygosity). With
NGS and highly sensitive PCR technologies, mutations
should be identifiable in specimens with as little as 10%
tumor (mutant allele frequency of 5% assuming heterozy-
gosity and diploidy). Lower analytically sensitive assays,
such as dideoxy sequencing, can be used, but it is recom-
mended that PCR enrichment strategies (eg, coamplification
at lower denaturation temperature-PCR) be used to increase
the analytical sensitivity of the test and require less tumor
percentage. A proper validation study should use cell line
DNA (preferably FFPE treated) or reference control material
manufactured by good manufacturing processes to assess
limit of detection for as many mutations as possible.
Importantly, the limit of detection may differ for mutations
of varying types (small indels vs point mutations).
Postanalytical Variables
Postanalysis is as important to consider in validation as
preanalytical and analytical variables. For single-gene
assays, the software used in analysis should be validated,
with verification of updates. If NGS is used, the bioinfor-
matics pipeline should be thoroughly and rigorously
validated, include potential problematic mutations
(eg, large indels), and be verified or revalidated for new
upgrades as applicable to the change. Any analysis should
be performed on validation specimens as it would be for
clinical specimens.
Reporting format should also be considered and decided
during validation. Interpretation comments for inclusion in
the patient report to ensure that the reports are correctly
understood should be developed during the validation pro-
cess.112 Human Genome Organisation (HUGO)ebased
nomenclature should be used for reports and a designated
National Center for Biotechnology Information (NCBI)
transcript number (NM_##) should be used within the
validation and report.116 For multigene panels based on
NGS, reporting protocols and any used software should be
included in the validation procedure. Databases and anno-
tation guidelines should be discussed and included in the
validation as one prepares to report variants based on NGS
data. In addition, decisions should be made during the
validation process as to whether normal tissue will be tested
to assist in variant interpretation with NGS.
In conclusion, validation of assays used in CRC molec-
ular testing is extremely important for accuracy of reporting
and proper patient care. There are several documents
(eg, CLIA, CAP, and CLSI)111-113,115 available to assist in212proper validation, which should be consulted to validate
according to best laboratory practices.
11. Strong Recommendation: Laboratories must vali-
date the performance of IHC testing for colorectal carci-
noma molecular biomarkers (currently IHC testing for
MLH1, MSH2, MSH6, and PMS2) in accordance with best
laboratory practices.
Four proteins (MLH1, MSH2, MSH6, and PMS2) are
currently considered important in the normal biochemistry
of DNA MMR.117-119 As detailed in recommendation 2b,
altered DNA mismatch repair proteins due to mutation or
epigenetic silencing result in interference with normal
MMR protein heterodimerization and loss of normal repair
of mispaired bases and short insertions/deletions, resulting
in MSI,119,120 overall categorized as dMMR. Loss of
MMR function usually correlates with loss of protein
expression, such that immunohistochemical testing for
MMR proteins is optimized to detect loss of MMR protein
expression in tumor cell nuclei. Each of these four proteins
can be detected in paraffin sections using commercially
available primary and secondary antibodies, standardized
antigen retrieval, and 3,3”-diaminobenzidine chromogen
detection. Development of anti-MMR protein antibody
staining protocols follows a standard approach that in-
volves (1) demonstration of absent background noise with
secondary antibody alone and (2) empirical optimization
of the signal-to-noise ratio by testing different antibody
concentrations, antigen retrieval buffers, and reaction
conditions, taking advantage of internal control cells,
including lymphocytes, stromal cells, and other nonneo-
plastic nuclei.
Validation of the final staining protocol is required prior to
implementation for clinical use. Peer-reviewed literature-
based guidelines for validation and revalidation of immuno-
histochemical tests have been defined as 14 recommendations
and expert consensus opinions.121 Concordance with internal
or external known comparator tests is required to exceed 90%.
Proficiency testing is a good approach to confirm interlabor-
atory test reproducibility. Test result concordance across
laboratories implies accuracy of participant laboratory
diagnosis.
Once the protocol is defined and validated for a given
primary antibody clone and antigen retrieval conditions, a
known positive external control (eg, tonsil) is routinely run
in parallel with each unknown. This demonstrates that the
MMR protein was detectable on that staining run and allows
trust in a loss of expression result in the unknown specimen.
Each of the four MMR proteins is expressed in nonneo-
plastic tissue, in most lymphocytes, and overexpressed in
germinal centers, such that most colon block sections will
also have positive internal control staining.
Overall, validated immunohistochemical detection of
MMR proteins is a trustworthy method for identification of
loss of expression of individual MMR proteins in paraffin
sections of CRC. In most CRCs with high-leveljmd.amjpathol.org - The Journal of Molecular Diagnostics
ASCP/CAP/AMP/ASCO CRC Biomarker Guidelinemicrosatellite instability (MSI-H), the loss of DNA MMR
protein expression in tumor cell nuclei by immunohisto-
chemical detection is uniform throughout the tumor.122,123
Rare cases of MSI tumors have been reported to show
heterogeneous staining.124 Loss of MMR protein expression
usually correlates with MSI, particularly for MSI-H tumors,
and is indicative of dMMR. If MSH2 or MLH1 shows loss
of expression due to loss of function, then their heterodimer
partners (MSH6 and PMS2, respectively) will also not be
expressed. In contrast, inactivation of MSH6 or PMS2 re-
sults in loss of expression of the individual MMR protein
MSH6 or PMS2, respectively.
Although loss of MMR protein immunoreactivity is
generally detected in dMMR CRC, normal immunoreac-
tivity can be seen in up to 10% of dMMR cases125; there-
fore, MSI DNA testing may be performed either stepwise or
as a concurrent test.
12. Expert Consensus Opinion: Laboratories must
provide clinically appropriate turnaround times and optimal
utilization of tissue specimens by using appropriate tech-
niques (eg, multiplexed assays) for clinically relevant
molecular and immunohistochemical biomarkers of CRC.
Expediency in reporting of biomarker results for colo-
rectal tumors is dictated primarily by two factors: need for
patient management decisions and, more generally, patient
anxiety. Consequently, results of such evaluations should be
available within a timeframe for the involved clinician to
relay this information to the patient. This need is com-
pounded by the patient’s need to receive a complete un-
derstanding of his or her diagnosis and treatment plans
going forward. A reasonable benchmark is that nonacute
biomarker results be available to the treating physician
within 10 working days of receipt in the molecular di-
agnostics laboratory. This turnaround time has been rec-
ommended in other guidelines for molecular tumor
testing.105,126,127 Ideally, the transitional time between test
ordering, tissue block selection, block retrieval, and ship-
ment to the performing laboratory should be included in the
10-day timeframe. Consequently, laboratories should make
every effort to minimize delays in securing appropriate tis-
sue blocks for testing. Testing laboratories should make
every effort to minimize processing time and return of
results.
The availability of tumor tissue for biomarker evaluation
is generally not limiting in most cases of resected CRC.
Occasionally, following neoadjuvant therapy, the amount of
residual tumor in resection specimens can be very small and
focal. Similarly, the amount of tumor tissue obtained by
biopsy or fine-needle aspiration procedures from primary or
metastatic foci can be very small and challenging to test for
the desired biomarkers. In such circumstances, available
tissue blocks should be sectioned judiciously, reserving
sufficient sections for testing by molecular methods or
immunohistochemical techniques, as deemed appropriate to
secure as accurate and informative an evaluation as possible.The Journal of Molecular Diagnostics - jmd.amjpathol.orgTest turnaround times for RAS testing in instances of
advanced stage tumors are dictated by the need to select and
initiate appropriate chemotherapy options. Ideally, such in-
formation should be available either at the time of post-
operative oncology evaluation, where decisions regarding
therapeutic options are entertained, or at the tumor boards
where patient treatment options are discussed. In some in-
stitutions, these discussions may occur in the week
following surgery or biopsy and probably no later than in
the second week following tissue diagnosis and staging.
Here, too, a timeframe of no more than 10 days would seem
an appropriate benchmark for biomarker result availability.
In exceptional circumstances, even shorter test turn-
around times may be called for. Occasional patients have
histories sufficiently suggestive of Lynch syndrome that
prompt consideration and discussion regarding extent of
surgery (ie, complete colectomy or prophylactic hysterec-
tomy in select affected patients). Efforts should be made in
such circumstances to obtain appropriate test results as
rapidly as possible to allow for informed decision making.
MMR immunohistochemistry can be performed and re-
ported with a turnaround time of 48 hours or less, and in the
appropriate clinical context, a result of preserved expression
of MMR proteins would argue against Lynch syndrome.
Conversely, any loss of MMR protein expression will need
to be integrated with additional clinical information, family
history, and further testing such as BRAF mutation, MLH1
methylation testing, and potential germline genetic testing.
Furthermore, DNA MMR status, performed by MMR
immunohistochemistry or by MSI DNA tests, as a good
prognostic biomarker for CRC overall, should be available
within the recommended 10 working day turnaround time
for test results.
13. Expert Consensus Opinion: Molecular and IHC
biomarker testing in colorectal carcinoma should be initiated
in a timely fashion based on the clinical scenario and in
accordance with institutionally accepted practices.
Note: Test ordering can occur on a case-by-case basis or
by policies established by the medical staff.
Molecular and IHC biomarker testing is increasingly
being used in patient management. Prognostic biomarkers
are being used for early stage disease to guide decisions on
the use of adjuvant chemotherapy. Such discussions require
the availability of tests in a timely manner, and delays in
initiation of therapy have been associated with worse out-
comes.127 Predictive biomarkers, such as those for EGFR
monoclonal antibody therapy, should be initiated in a timely
fashion to guide chemotherapy options and long-term
treatment planning. Institutional policies and practices that
encourage the rapid initiation of appropriate molecular and
IHC marker testing should be encouraged. Such policies
may include reflexive ordering of molecular and IHC
markers as guided by the clinical scenario and incorporation
of testing initiation by multiple members of the multidisci-
plinary team, as noted in recommendation 15.213
Sepulveda et al14. Expert Consensus Opinion: Laboratories should
establish policies to ensure efficient allocation and utiliza-
tion of tissue for molecular testing, particularly in small
specimens.
The number of molecular and immunohistochemical tests
becoming available that have a direct benefit to patient care
will continue to increase. Most of these tests are performed
on FFPE specimens, the most common preservation tech-
nique, including pretreatment and posttreatment biopsies
and resections (Table 13). Tissues from patients with cancer
should be processed according to established laboratory
protocols, which include quality controls of preservation
materials, tissue dissection, time to fixation, fixation time,
and processing.
Laboratory protocols need to include procedures for
handling small samples such as endoscopic or core biopsy
specimens and fine-needle aspirate samples of metastatic le-
sions (eg, from liver or lung). Limiting the number of tissue
fragments per individual cassette is encouraged. Established
protocols may allow upfront ordering of required tissue sec-
tions (eg, extra unstained slides), which limit tissue wasting
and improve turnaround time of final results. Immunohisto-
chemistry studies, if needed to diagnose metastatic CRC,
should be limited in scope and standardized to preserve tissues.
It is imperative to identify suspected metastatic CRC
specimens at specimen accessioning to limit unneeded
ancillary tests, such as liver biopsy special stains. Recog-
nition of previous CRC diagnoses from the patient clinical
history should limit the need for immunohistochemistry
profiles in many cases. Established laboratory procedures to
identify patients undergoing cancer biopsy or fine-needle
aspiration specifically for predictive molecular biomarker
assessments need to be in place.
Laboratories must maintain appropriate cataloguing and
storage of tissue specimens and diagnostic slides to allow
for retrospective timely testing of cancer samples.
This recommendation is supported by 15 studies,128-142
comprising eight prospective cohort studies130-133,136-138,142
and seven retrospective cohort studies.128,129,134,135,139-141
For the eight prospective cohort studies,130-133,136-138,142
all reported balance between the treatment and assessment
groups, as all but one132 used a single cohort design
allowing for within-group comparisons. Only this single
study, reported by Tol et al,132 would have required making
adjustments for imbalances between the treatment and
assessment groups, but none were needed. Five
studies130,133,136-138 reported nonindustry funding, one132
reported at least partial industry funding, one142 reported
industry funding, and one131 did not disclose the source of
funding, if any. Seven130,131,133,136-138,142 were deemed to
have a low risk of bias, and one132 was deemed to have a
low to moderate risk of bias.
For the seven retrospective cohort
studies,128,129,134,135,139-141 all used a single cohort design
allowing for within-group comparisons. Four reported
nonindustry funding,134,135,139,140 one reported industry214funding,129 and two did not disclose the source of funding,
if any.128,141 Six were deemed to have a low risk of
bias,128,134,135,139-141 and one was deemed to have a mod-
erate risk of bias.129
All of the evidence that supported this recommendation
was assessed, and none had methodologic flaws that would
raise concerns about their findings.
15. Expert Consensus Opinion: Members of the pa-
tient’s medical team, including pathologists, may initiate
colorectal carcinoma molecular biomarker test orders in
accordance with institutionally accepted practices.
For patients with CRC, timely diagnosis or therapeutic
initiation is critical, and molecular testing that is to be
considered should be ordered as efficiently as possible in
accordance with institutional practices and guidelines. MSI
testing is often ordered at the time of diagnosis to identify
patients with Lynch syndrome, direct adjuvant chemo-
therapy, or determine prognosis. Many institutions employ
algorithms to ensure that all colorectal cancers are evaluated
for MMR deficiency, and these are often initiated by pa-
thologists when the diagnosis occurs after joint general
process approval by pathologists, oncologists, and other
members of the patient medical team. Molecular testing that
is performed to direct targeted therapy (eg, RAS ) may be
ordered at a later date than the primary diagnosis, at meta-
static presentation, for example, and so institutions may
differ as to whether one should order such testing upfront on
the primary diagnostic biopsy or resection specimen or wait
until metastatic disease arises requiring targeted therapy.
Often oncologists order predictive molecular assays since
they are used to direct therapy, but this should not neces-
sarily be limited to oncologists, as pathologists serve as
important stewards of the tissue and make the tumor diag-
nosis. There are also issues to consider, including logistical
issues, cost-effectiveness, patient access to molecular testing
in rural or underserved areas, and even heterogeneity con-
siderations between primary and metastatic tumor. Since
each institution differs in patient population, facilities,
departmental organization, regulatory and reimbursement
climates, and practitioner preference, whether to submit
testing at initial diagnosis of a primary lesion or when a
metastatic lesion arises should be discussed collaboratively
between oncologists, pathologists, and medical executive or
hospital committees as applicable.
“Reflex” testing, a testing policy that does not require a
separate clinician order for each case, is appropriate if
agreed upon by the CRC care team as an institutionally
approved standing order and may help to ensure expedited
and consistent routing of specimens for molecular testing.
However, some patients may not be candidates for targeted
therapy for clinical reasons, and good communication be-
tween the clinical care team and the testing laboratory is
needed to ensure testing is performed for patients whose
management will be affected by the test result. Specifically,
testing is not necessary for patients with stage IV diseasejmd.amjpathol.org - The Journal of Molecular Diagnostics
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only. Similarly, in settings in which reflex testing is the
practice, a mechanism should be provided for the clinical
care team to communicate to the pathologist examining a
small biopsy or cytology sample when a more suitable
diagnostic specimen (eg, a resection) is expected to be ob-
tained, and the molecular testing should be deferred to the
subsequent, more generous sample. All reflex testing should
be approved institutionally by the hospital or institution’s
medical executive committee as local policies dictate.
16. Expert Consensus Opinion: Laboratories that
require send out of tests for treatment predictive biomarkers
should process and send colorectal carcinoma specimens to
reference molecular laboratories in a timely manner.
Note: It is suggested that a benchmark of 90% of speci-
mens should be sent out within 3 working days.
It is critical to provide the results of molecular tests in a
timely fashion to start the most appropriate cancer treatment
option for each patient. Delays in initiation of therapy have
been associated with worse outcomes.127 To date, labora-
tories have had limited guidance on the recommended
timing or turnaround time of molecular test results, and
studies addressing the impact of specific turnaround times
have not been conducted. Therefore, the panel reached an
expert consensus opinion, based on each panel member’s
practical experience in the laboratory and clinical setting.
For laboratories that do not perform molecular testing
and/or biomarker immunohistochemistry for CRC therapy
selection, the consensus opinion was that send out of
specimens should occur within 3 working days, starting
from the day the test order was received in the laboratory,
provided the specimens (eg, biopsy or resection specimens)
are received at the same time of the test order or specimens
are already in the laboratory (eg, archived paraffin blocks).
The underlying rationale stems from the usual workflow for
tissue processing. In practice, the longest process would be
the processing of large surgical specimens, such as colec-
tomies. A possible approach is to obtain a designated mo-
lecular tissue block at the time of specimen grossing, and
molecular protocols for obtaining tissue sections may be
used to have the necessary sections for test send-out in a
timely fashion by the third working day for most cases.
Another scenario may be the retrieval of archived tissue
paraffin blocks that may be stored outside of the laboratory
location. In this case, a protocol for block retrieval for
molecular testing may be operationalized to streamline the
process and reach the desired turnaround time for send-out.
This turnaround time of 3 working days was also recom-
mended for RAS testing of colorectal carcinoma in the
guidance document from the Association of Clinical Pa-
thologists Molecular Pathology and Diagnostics Group in
the United Kingdom.126
Laboratories should develop written policies as part of
their quality assurance program to monitor turnaround times
for all cancer therapeutic and prognostic biomarkers.The Journal of Molecular Diagnostics - jmd.amjpathol.org17. Expert Consensus Opinion: Pathologists must eval-
uate candidate specimens for biomarker testing to ensure
specimen adequacy, taking into account tissue quality,
quantity, and malignant tumor cell fraction. Specimen ade-
quacy findings should be documented in the patient report.
It is critical that pathologists selecting blocks for
biomarker testing understand the specimen requirements of
the method being employed in terms of total tissue amount
(a reflection of the total amount of DNA required for the
assays) and the fraction of malignant tumor cells in the
specimen focus to be evaluated. The total amount of tissue
selected for evaluation is significant in two respects. First, the
amount of tissue sampled should be of sufficient quantity to
produce a result that is reliably representative of the entire
tumor. While recent evidence indicates that some genes
continue to evolve during tumor progression, leading to
substantial tumor genetic heterogeneity, those driver muta-
tions of importance to CRC are usually, but not always, ho-
mogeneous throughout the tumor. The amount of tumor
necessary, however, for a particular analytical method can
vary and demands knowledge and due attention to the indi-
cated tissue requirements for the specific assay employed.
The minimal required proportion of tumor DNA in a sample
from cancer is dictated by the analytical sensitivity of the
particular validated assay. As shown in Table 13, the amount
of tumor used in the analyses of KRAS mutations in several
studies comparing the test-performing characteristics of
various assays varied widely, ranging from 1% to 90%.
The proportion of malignant tumor cells (as opposed to
tumor-associated nonmalignant cells, eg, stromal fibro-
blasts, endothelial cells, infiltrating inflammatory cells)
should be evaluated as accurately as possible and docu-
mented. This evaluation is most readily performed by esti-
mating the proportion of malignant cell nuclei to
nonmalignant cell nuclei within the focus selected for
evaluation.143 Understanding that the number of mutated
alleles for a particular gene may represent as few as half of
the alleles in diploid tumor cells, a tumor cell focus with a
nominal proportion of 50% tumor cells would have a mutant
allele fraction of 25%, a value approaching the analytical
sensitivity of some molecular assays. So, while variety of
molecular methods can be used to evaluate tissue speci-
mens, it is critical that these be carefully matched to their
specific tissue and tumor cell proportion requirements.
When adhered to, all these of these methods can produce
accurate and reliable results.
Pathologists evaluating tissue section for biomarker
evaluation should also be aware that necrosis and tissue
degeneration can lead to erroneous results, and foci
demonstrating significant necrosis should be avoided for
molecular testing. Any amount of necrosis in the sample
selected for biomarker testing should be estimated and
documented.
18. Expert Consensus Opinion: Laboratories should use
colorectal carcinoma molecular biomarker testing methods215
Sepulveda et althat are able to detect mutations in specimens with at least 5%
mutant allele frequency, taking into account the analytical
sensitivity of the assay (limit of detection or LOD) and tumor
enrichment (eg, microdissection).
Note: It is recommended that the operational minimal
neoplastic carcinoma cell content tested should be set at
least two times the assay’s LOD.
Since the accuracy and results of testing for molecular
markers are dependent on both tumor cell content and the
assay-specific sensitivity in the identification of a mutant
allele against a background of wild-type/nonmutated alleles,
it is suggested that laboratories should establish minimum
acceptable tumor cell content as a component of their
specimen requirements. It is recommended that a patholo-
gist reviews all cases for tumor cell content and quality. Due
to the stochastic nature of mutant allele identification at the
lower LOD, it is recommended that the minimal tumor cell
content be at least two times the lower LOD of a validated
molecular method or assay. This LOD was also recom-
mended for RAS testing of colorectal carcinoma in the
guidance document from the United Kingdom.126 Hence, if
a particular assay has a lower limit of mutant allele detection
of 5%, then the minimum tumor cell content in samples
analyzed by this assay should be at least 10% to reliably
detect heterozygous mutations in those neoplasms. Due to
intratumoral heterogeneity, subclones, and the nature of
tissue sampling, clinical trials have used 5% as the lower
LOD, and for clinical purposes, it is recommended that the
lower LOD for a mutant allele be at least 5%.12 Therefore,
the utilization of methods such as PCR, HRM, single-strand
conformation polymorphism, pyrosequencing, or commer-
cially available kits that achieve this level of sensitivity is
recommended130,137,138,142 (Table 13).
This recommendation is supported by four prospective
cohort studies130,137,138,142 and two retrospective cohort
studies.102,144 The four prospective cohort studies all studied
a single cohort, allowing for within-group comparisons. For
this reason, all were balanced between comparison groups,
and no adjustments were needed to account for baseline
differences. All four reported nonindustry funding, and all
were deemed to have a low risk of bias.
The two retrospective cohort studies102,144 also used
single cohorts, allowing for within-group comparisons only.
One102 did not report the source of funding, while the
other144 reported nonindustry funding. Both were deemed to
have a low risk of bias.
None of the studies had methodologic flaws that would
raise concerns about their findings.
19. Expert Consensus Opinion: Colorectal carcinoma
molecular biomarker results should be made available as
promptly as feasible to inform therapeutic decision making,
both prognostic and predictive.
Note: It is suggested that a benchmark of 90% of reports
be available within 10 working days from date of receipt in
the molecular diagnostics laboratory.216Combined chemotherapy, including anti-EGFR therapy,
in patients with CRC in the absence of mutations in the
EGFR signaling pathway is associated with significant
survival advantage. No significant therapeutic benefit is
derived from anti-EGFR therapy in the presence of muta-
tions in KRAS and NRAS.44 The presence of deficient MMR
in stage II CRC indicates a good prognosis and identifies
patients for whom adjuvant 5-fluorouracil mono-based
therapies have no significant benefit.145,146 The presence
of deficient MMR or BRAF p.V600E mutation in proficient
MMR CRCs has important prognostic significance.54
In the absence of published data establishing an evidence-
based recommendation, it is our expert consensus opinion
that the above results, regardless of testing methods, be
available from test ordering in the initial diagnostic pathology
laboratory to the clinical team within 2 weeks (10 working
days). The 10 working days does not include the time before
the tissue specimen is available for testing (ie, from diag-
nostic procedure to receipt in laboratory) or time to retrieve
tissue samples from an outside laboratory. Laboratories un-
able to maintain this standard, either through in-house testing
or use of a reference laboratory, need to implement measures
to improve test result turnaround time. A turnaround time of
7 working days was recommended for RAS testing of colo-
rectal carcinoma in the guidance document from the Asso-
ciation of Clinical Pathologists Molecular Pathology and
Diagnostics Group in the United Kingdom.126
This recommendation is supported by evidence from one
randomized controlled trial, reported by Douillard et al.44
This report used prospective patient data collected within
the PRIME trial. While it did not report details on the
randomization, blinding, statistical power calculation, sam-
ple size, or length of follow-up, it did report on baseline
characteristics and was otherwise well reported. Funding
was reported to be partially from industry sources. Overall,
this trial was found to have a low to moderate risk of bias
and did not have methodologic flaws that would raise
concerns about its findings.
Each laboratory should develop a quality assurance pro-
gram to monitor turnaround times for all cancer therapeutic
and prognostic biomarkers.
20. Expert Consensus Opinion: Colorectal carcinoma
molecular biomarker testing reports should include a results
and interpretation section readily understandable by oncol-
ogists and pathologists. Appropriate Human Genome Vari-
ation Society (HGVS) and HUGO nomenclature must be
used in conjunction with any historical genetic designations.
Reporting of molecular results is becoming more com-
plex as new information and clinical utility are discovered
for somatic variants. Single-gene assays are still being
widely used, but multiplexing has allowed for multiple
possible results. With the introduction of NGS into the
clinical setting, multiple somatic mutations with clinical
significance may be identified. However, panel assays by
NGS can also reveal variants with unknown clinicaljmd.amjpathol.org - The Journal of Molecular Diagnostics
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have been discovered over the past 30 years, there has been
divergent nomenclature employed, making clinical report-
ing and clinical analysis difficult. Presently and in the
future, as national databases are constructed annotating
clinical somatic variants, it is imperative that standardized
nomenclature be employed to identify the clinical signifi-
cance of rare variants.
Clinicians want a report that is easily readable and un-
derstandable but that gives pertinent clinical information
concisely, accurately, and thoroughly. Reported variants
should be identified using both DNA and protein nomen-
clature. Citing codon positivity only is not encouraged (eg,
positive for a KRAS codon 12 mutation). The specific mu-
tation should be explained using standardized nomenclature,
preferably HUGO gene nomenclature.112,147 Historical des-
ignations (eg, historical HER-2/neu, for HUGO ERBB2)
should also be included as appropriate in the report to avoid
confusion among oncologists. Importantly, the messenger
RNA transcript number (NM_#) from the NCBI, used to
designate the specific codon numbering, should be named in
the report since numbering can differ between the different/
alternative transcript designations for the same gene. If using
NGS, variants should at least be classified as pathogenic,
likely pathogenic, variant of unknown significance, likely
benign, or benign, but classification of somatic mutations is
still awaiting specifically approved guidelines.148 How-
ever, a numerical classification scheme for somatic variants
has been proposed, taking into consideration actionability
of the variant in the patient’s tumor type vs other tumor
types, predicted pathogenicity (using programs such as
SIFT and PolyPhen 2) in the patient’s tumor type vs other
tumor types, variant recurrence in a certain cancer type, or
unknown significance.149 Such a classification scheme
may be better suited to somatic variants considering the
indications for which most of these assays are being
ordered.
Reports should contain the analytical result, the method
used, and information about the genes and loci tested or
included in the assay; the assay limit of detection; and any
disclaimers (eg, ASR) that are required to meet regulations.
When reasonable and applicable, an interpretive comment
should be given to ensure that results are correctly under-
stood.112 Such an interpretive comment may include infor-
mation regarding therapeutic implications, prognostic
implications, and/or pathogenic significance of the mutation
and, when appropriate or desired, potential applicable clin-
ical trials.
In summary, molecular reports should be easily under-
standable by clinical oncologists and use standardized
nomenclature outlined by HGVS/HUGO. All reports should
contain the elements of result, interpretation, variant clas-
sification, and information as applicable; limit of detection
of the assay and methods to assist the oncologist in under-
standing the test result; and limitations as they consider the
result in a clinical context.The Journal of Molecular Diagnostics - jmd.amjpathol.org21. Strong Recommendation: Laboratories must incor-
porate colorectal carcinoma molecular biomarker testing
methods into their overall laboratory quality improvement
program, establishing appropriate quality improvement
monitors as needed to ensure consistent performance in all
steps of the testing and reporting process. In particular,
laboratories performing colorectal carcinoma molecular
biomarker testing must participate in formal proficiency
testing programs, if available, or an alternative proficiency
assurance activity.
Proficiency testing (PT) is an important component of
quality assurance for laboratory tests in general and applies
to the molecular tests discussed in the current CRC mo-
lecular testing guidelines. These include mutational as well
as immunohistochemical testing. Participation in PT allows
the assessment and comparison of test performance among
different clinical laboratories and technologies and allows
verification of accuracy and reliability of laboratory
tests.150
From a regulatory standpoint, PT in the United States is a
requirement for accreditation by the Centers for Medicare &
Medicaid Services. Participation in PT may be done through
CAP PT programs or through other providers accepted
by CLIA.151 Other countriesdnamely, the United
Kingdomdfollow similar guidelines, recommending that
laboratories providing RAS testing of CRC should demon-
strate successful participation in a relevant external quality
assurance scheme and be appropriately accredited.126
Formal external proficiency testing programs for analytes
other than KRAS, MSI, MMR, and BRAF may not be
available at the time of this publication. Alternative profi-
ciency testing activities should be used. Appropriate alter-
native performance assessment procedures may include
split sample analysis with other laboratories or, if that is not
available, assessment of split samples with an established
in-house method and previously assayed material, which are
run and interpreted by laboratory personnel who do not
have access to the prior results.151 If exchanging specimens
with other laboratories is the laboratory proficiency
approach, this should be done with one or more other lab-
oratories at least twice per year.105 Methods-based profi-
ciency testing (MBPT) refers to a testing approach that is
based on method, rather than based on each individual an-
alyte tested. MBPT is well established for several pathology
subspecialty areas, and the concept of MBPT complies with
federal laboratory regulations.151Discussion on Emerging Biomarkers
Numerous studies have reported potential molecular bio-
markers for CRC prognosis, while fewer studies evaluated
markers that could be predictive of response to specific
treatments. Many published studies are limited due to early
exploratory and retrospective analyses, and those bio-
markers, while of potential interest, have not made it to217
Sepulveda et alclinical practice. Our systematic review identified several
CRC molecular biomarkers that showed either prognostic or
treatment predictive characteristics in single studies
(Supplemental Table 15). Most of the molecular biomarkers
reported in the studies listed in the Supplemental Table 15
were tested for expression by immunohistochemistry.
Immunohistochemistry is notable for its widespread avail-
ability in pathology laboratories but has limited quantitative
capabilities due to difficult standardization of quantitative or
semiquantitative scoring, and is fraught by significant
interobserver variability. A problem of quantitative assays,
such as gene expression, microRNA expression, and
methylation levels, tested in solid tumors, results from the
intrinsic mixed nature of the tissue with significant vari-
ability of tumor and nontumor tissue content. Another
limitation of molecular biomarker discovery approaches that
rely on expression levels is that these biomarkers have not
been evaluated in the context of complex molecular regu-
lation of individual cancer subtypes. Their fruitful use in the
clinic may require further studies that take into account
computational predictions of biological behavior and vali-
dation in prospective cohorts.
A great deal of interest has been raised recently for
noninvasive prognostic and/or therapy-predictive molecular
biomarkers, such as those tested in circulating tumor cells or
circulating nucleic acids, either as free nucleic acid in serum
or associated with extracellular vesicles or exosomes. This
has been referred to as “liquid biopsy.”152 Liquid biopsies
may be particularly useful in the management of patients with
CRC to identify recurrence, RAS mutation testing for emer-
gence of treatment resistance associated with anti-EGFR
therapy, and potential early cancer detection in defined sub-
populations, such as those at high risk of CRC. Overall,
molecular biomarkers for colorectal cancer tested in liquid
biopsy samples are promising but await further validation.
Emerging data indicate that MMR status may have pre-
dictive value in some settings, specifically in patients with
advanced disease being considered for anti-PD-1/PD-L1
therapy.68,69Conclusions
Evidence supports mutational testing of specific genes in the
EGFR signaling pathway, since they provide clinically
actionable information for targeted therapy of CRC with
anti-EGFR monoclonal antibodies. Mutations in some of
the biomarkers have clear prognostic value (BRAF, MMR),
and at least two (KRAS and NRAS ) have relatively strong
evidence as negative predictors of benefit to anti-EGFR
therapies and should be used to guide the use of these
agents. BRAF mutations are consistently associated with
poor outcomes in patients with metastatic CRC, including
those who relapse after adjuvant therapy. Patients with
localized colon cancer and dMMR have improved out-
comes. Emerging data suggest that MMR status has218predictive value in some settings, specifically in patients
with advanced disease being considered for anti-PD-1/PD-
L1 therapy.
Laboratory approaches to operationalize molecular
testing for predictive and prognostic molecular biomarkers
involve selection of assays, type of specimens to be tested,
timing of ordering of tests, and turnaround time for testing
results. A number of alternative technical approaches can
effectively be used as long as test specificity and sensitivity
meet the clinical needs. While earlier testing approaches
were focused on one or a few testing targets (eg, BRAF
p.V600 mutations), currently, new approaches are using
gene panels such as targeted NGS cancer panels, which can
range from a few to hundreds of genes and amplicons with
known mutational hotspots in cancer.
These guidelines will be subjected to regular updates,
such that new advances in the field can be captured and
integrated in the guidelines in a timely manner.
This guideline was developed through collaboration
between the American Society for Clinical Pathology,
College of American Pathologists, Association for Molec-
ular Pathology, and American Society of Clinical Oncology
and has been jointly published by invitation and consent in
the American Journal of Clinical Pathology, Archives of
Pathology & Laboratory Medicine, Journal of Molecular
Diagnostics, and Journal of Clinical Oncology. It has been
edited in accordance with standards established at the
American Journal of Clinical Pathology.
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